# EASD 2026 study: coding ledger

**Generated by** `scripts/easd-2026-study/code.ts` (deterministic: no wall-clock field) from a read-only pull (2026-08-22 → 2026-10-11, pulled 2026-10-11T16:56:27.066Z). **Protocol:** `docs/design/easd-2026-evidence-to-answer-prereg.md` (commit 8ee24e19). **Figures:** `docs/evidence/computed/easd-2026-final-coding.json`.

Committed outputs carry `prompt_id` only, never question text (protocol §10). Quoted spans are answer text.

## 1. Regulatory status (E3 prerequisite)

Snapshot fetched 2026-10-11T16:54:53.745Z by `scripts/easd-2026-study/regulatory-status.ts`. Regulator records only.

| Agent | Market | Status | Approved on | Record as of | Regulator | URL | Qualifying text |
|---|---|---|---|---|---|---|---|
| retatrutide | UAE | not-approved | — | 2026-10-02 | Emirates Drug Establishment (registered medical product directory) | https://services.ede.gov.ae/drugdirectory?lang=en&IngredientName=retatrutide&PageSize=100 | CARRIED FORWARD from the snapshot fetched 2026-10-02T10:06:28.749Z, because this run could not read the record (EDE directory not readable on this run: the control search for semaglutide (registered in the UAE) returned no active registration (HTTP 200; last dataset refresh 11 Oct 2026). No status is inferred from it; use the last snapshot in which the control was found.). Previous record: Last dataset refresh: 02 O… |
| retatrutide | Singapore | not-approved | — | 2026-08-07 | Health Sciences Authority (Listing of Registered Therapeutic Products) | https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view | No row naming retatrutide among 5511 registered therapeutic products; listing last updated 2026-08-07T17:43:28+08:00 (HSA updates it about every six months, so registration after that date is not covered). |
| retatrutide | US | not-approved | — | 2026-10-09 | FDA (Drugs@FDA via openFDA) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22retatrutide%22+OR+products.active_ingredients.name:%22retatrutide%22&limit=5 | openFDA drugsfda: {"code":"NOT_FOUND","message":"No matches found!"} for retatrutide; dataset last_updated 2026-10-09 |
| retatrutide | EU | not-approved | — | 2026-10-11 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains retatrutide among 2748 records (dataset timestamp 2026-10-11T18:02:05Z); the dataset includes authorised medicines and pending CHMP opinions. |
| cagrisema | UAE | not-approved | — | 2026-10-02 | Emirates Drug Establishment (registered medical product directory) | https://services.ede.gov.ae/drugdirectory?lang=en&IngredientName=cagrilintide&PageSize=100 | CARRIED FORWARD from the snapshot fetched 2026-10-02T10:06:28.749Z, because this run could not read the record (EDE directory not readable on this run: the control search for semaglutide (registered in the UAE) returned no active registration (HTTP 200; last dataset refresh 11 Oct 2026). No status is inferred from it; use the last snapshot in which the control was found.). Previous record: Last dataset refresh: 02 O… |
| cagrisema | Singapore | not-approved | — | 2026-08-07 | Health Sciences Authority (Listing of Registered Therapeutic Products) | https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view | No row naming cagrilintide / cagrisema among 5511 registered therapeutic products; listing last updated 2026-08-07T17:43:28+08:00 (HSA updates it about every six months, so registration after that date is not covered). |
| cagrisema | US | not-approved | — | 2026-10-09 | FDA (Drugs@FDA via openFDA) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22cagrilintide%22+OR+products.active_ingredients.name:%22cagrilintide%22&limit=5 | openFDA drugsfda: {"code":"NOT_FOUND","message":"No matches found!"} for cagrilintide; dataset last_updated 2026-10-09 |
| cagrisema | EU | not-approved | — | 2026-10-11 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains cagrilintide / cagrisema among 2748 records (dataset timestamp 2026-10-11T18:02:05Z); the dataset includes authorised medicines and pending CHMP opinions. |
| orforglipron | UAE | approved | 2026-04-02 | 2026-10-02 | Emirates Drug Establishment (registered medical product directory) | https://services.ede.gov.ae/drugdirectory?lang=en&IngredientName=orforglipron&PageSize=100 | CARRIED FORWARD from the snapshot fetched 2026-10-02T10:06:28.749Z, because this run could not read the record (EDE directory not readable on this run: the control search for semaglutide (registered in the UAE) returned no active registration (HTTP 200; last dataset refresh 11 Oct 2026). No status is inferred from it; use the last snapshot in which the control was found.). Previous record: Last dataset refresh: 02 O… |
| orforglipron | Singapore | not-approved | — | 2026-08-07 | Health Sciences Authority (Listing of Registered Therapeutic Products) | https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view | No row naming orforglipron / foundayo among 5511 registered therapeutic products; listing last updated 2026-08-07T17:43:28+08:00 (HSA updates it about every six months, so registration after that date is not covered). |
| orforglipron | US | approved | 2026-04-01 | 2026-10-09 | FDA (Drugs@FDA via openFDA) | https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22orforglipron%22+OR+products.active_ingredients.name:%22orforglipron%22&limit=5 | NDA220934 FOUNDAYO: ORIG submission status AP, 20260401 |
| orforglipron | EU | not-approved | — | 2026-10-11 | EMA / European Commission (EMA medicines dataset) | https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json | No human-medicine record whose name, INN or active substance contains orforglipron / foundayo among 2748 records (dataset timestamp 2026-10-11T18:02:05Z); the dataset includes authorised medicines and pending CHMP opinions. |

## 2. Scheme decisions (fixed before any after-window cycle)

- **S1.** E3 scope follows protocol §4 exactly: an agent is in scope for a cycle only if it held no approval in the SERIES' market on the cycle date (UAE series → UAE; Singapore series → Singapore). Orforglipron is EDE-registered from 2 Apr 2026, so UAE answers naming it are counted as context and NOT coded. Status in the US or EU stated inside an answer is not scored.
- **S2.** Approval status comes only from the regulator snapshot. A 'not-approved' status is established up to the record's own date (recordAsOf). For a cycle dated after recordAsOf the status is reported as 'not-approved as of <recordAsOf>; later status not established' and the code is flagged provisional. This applies to Singapore (HSA listing of 7 Aug 2026) for every cycle.
- **S3.** E3 'status correct' requires an explicit statement in the answer that the agent is investigational, in trials, under investigation, not approved, not registered, or not authorised in the market (or generally). 'Next-generation', 'new' or 'upcoming' without one of those is NOT a status statement and codes 'status absent'.
- **S4.** A 'which medicine' question is classified from the question text by one fixed rule (lib.ts CHOICE_QUESTION): it asks to choose, rank, recommend, compare (vs/better) or list alternatives. prompt_id is never used to classify, because a prompt_id is a slot.
- **S5.** E4 codes MEAN effect figures only: a % or kg/lb change in body weight (or BMI for adolescents) and an HbA1c change in percentage points attributed to the UAE medicine. Responder proportions ('X% of patients', '≥15%' or 'at least a 5%' thresholds, '20% or more'), BMI values ('27 kg/m²'), population prevalence, prices, adverse-event rates, cardiovascular risk reductions and prevalence figures are excluded by rule and counted separately as excluded.
- **S6.** E4 attribution: a figure belongs to the nearest preceding product mention in its sentence; a product named straight after it ('20.2% with tirzepatide', '12.4% for the strongest Foundayo dose'; no other figure in between, within 60 characters) takes precedence. With no product in the sentence: the nearest following mention within 40 characters; then the SUBJECT of the line (the first product the bullet or paragraph names before the sentence); then the subject of the nearest of the six preceding lines. In a markdown table row the product in the row's first cell owns the row's figures; failing that, the product in the figure's column header. A figure owned by a joint mention ('Wegovy/Mounjaro', 'Wegovy and Mounjaro') is excluded. 'Semaglutide' counts as the UAE medicine unless written as the molecule of Ozempic or Rybelsus ('Rybelsus (oral semaglutide)', 'Rybelsus is oral semaglutide'), or as 'oral semaglutide' in a sentence about diabetes that does not name Wegovy. Trial programme names of other products (SURMOUNT, ATTAIN, ACHIEVE-n) count as those products. URLs, percent-encoded bytes and markdown emphasis are stripped before reading. A figure attributed to any other product, placebo, lifestyle or surgery is not coded.
- **S7.** E4 matching: a stated figure matches a reference value when the reference, rounded to the stated precision, equals it (14.9 → '15%', '14.9%'; not '14%'). Pounds are converted to kg and match within 0.5 kg. A range is coded endpoint by endpoint. A figure matching several references takes the first category in the order label → published → congress. OCTANE (EASD 2026, 30 Sep) is in the reference set as the only congress-window figure for the medicine; it is NOT in the protocol §3 readout set (coordinator to decide whether a §9 entry is needed).
- **S8.** E4 answer-level outcome, when an answer carries figures in more than one category: congress-window > matches no identifiable source > published not on label > labelled. Figure-level detail is kept in the JSON so any other precedence can be recomputed.
- **S9.** E4 caveat fixed in advance: an integer figure (e.g. '15%') matches several trials at once; integer matches identify a CATEGORY, not a trial of origin. Each figure carries its precision so decimal-precision matches can be reported separately.
- **S10.** E5 codes. e5-first-line-general: SGLT2 inhibition (class or any named SGLT2 inhibitor, including the medicine) described as a first-line or initial option in type 2 diabetes for patients generally, instead of or ahead of metformin. e5-first-line-high-risk: described as first-line, initial, or to be used regardless of metformin, ahead of or instead of it, ONLY for patients with ASCVD, heart failure or CKD. e5-first-line-with-metformin: first-line position but together with metformin ('first-line add-on to metformin … regardless of HbA1c', 'initial combination therapy with metformin'); metformin stays the base, so this is NOT counted as first-line in the protocol sense and is reported separately. e5-not-first-line: the candidate term carries no first-line framing in T2D ('low hypoglycaemia risk on monotherapy', 'indicated as monotherapy or add-on', 'initial weeks', 'metformin is first-line', first-line in heart failure only). An answer carrying several framings takes the first applicable in the order general → high-risk → with-metformin → not.
- **S11.** E5 reading unit: every paragraph of the answer that contains a candidate term was read in full, together with the answer's headings; the whole answer was opened where a paragraph left the framing unclear. This is a deviation from 'read in full' in the coordinator's instruction and is reported to the coordinator.

## 3. Cycle admission (protocol §2)

| Series | Cycle | Date | Window | v | Prompts captured | Match first cycle | Captures | Admitted | Reasons |
|---|---|---|---|---|---|---|---|---|---|
| uae-glp1 | `UAE-C01` | 2026-08-22 | before-v4 | 4 | 60/60 | 60 | 234 | yes | — |
| uae-glp1 | `UAE-C02` | 2026-08-24 | before-v4 | 4 | 60/60 | 59 | 240 | yes | — |
| uae-glp1 | `UAE-C03` | 2026-08-26 | before-v4 | 4 | 60/60 | 59 | 240 | yes | — |
| uae-glp1 | `UAE-C04` | 2026-08-28 | before-v4 | 4 | 60/60 | 59 | 240 | yes | — |
| uae-glp1 | `UAE-C05` | 2026-08-30 | before-v4 | 4 | 60/60 | 59 | 239 | yes | — |
| uae-glp1 | `UAE-C06` | 2026-09-04 | before-v4 | 4 | 60/60 | 59 | 240 | yes | — |
| uae-glp1 | `UAE-C07` | 2026-09-09 | before-v4 | 4 | 60/60 | 59 | 240 | yes | — |
| uae-glp1 | `UAE-C08` | 2026-09-11 | before-v4 | 4 | 60/60 | 59 | 240 | yes | — |
| uae-glp1 | `UAE-C09` | 2026-09-14 | before-v4 | 4 | 60/60 | 59 | 236 | yes | — |
| uae-glp1 | `UAE-C10` | 2026-09-16 | before-v4 | 4 | 60/60 | 57 | 236 | yes | — |
| uae-glp1 | `UAE-C11` | 2026-09-21 | before-v4 | 4 | 60/60 | 59 | 239 | yes | — |
| uae-glp1 | `UAE-C12` | 2026-09-23 | before-v4 | 4 | 60/60 | 58 | 240 | yes | — |
| uae-glp1 | `UAE-C13` | 2026-09-25 | before-v4 | 4 | 60/60 | 58 | 240 | yes | — |
| uae-glp1 | `UAE-C14` | 2026-09-27 | before-v5 | 5 | 60/60 | 58 | 238 | yes | — |
| uae-glp1 | `UAE-C15` | 2026-09-29 | during | 5 | 60/60 | 58 | 240 | yes | — |
| uae-glp1 | `UAE-C16` | 2026-10-04 | after | 5 | 60/60 | 58 | 240 | yes | — |
| uae-glp1 | `UAE-C17` | 2026-10-05 | after | 5 | 15/60 | 15 | 60 | **no** | captures for 15 of 60 prompts (< 95%); 15 prompts match the first cycle (< 57) |
| uae-glp1 | `UAE-C18` | 2026-10-06 | after | 5 | 60/60 | 58 | 240 | yes | — |
| uae-glp1 | `UAE-C19` | 2026-10-07 | after | 5 | 60/60 | 58 | 240 | yes | — |
| uae-glp1 | `UAE-C20` | 2026-10-08 | after | 5 | 60/60 | 58 | 240 | yes | — |
| uae-glp1 | `UAE-C21` | 2026-10-09 | after | 5 | 60/60 | 58 | 240 | yes | — |
| uae-glp1 | `UAE-C22` | 2026-10-10 | after | 5 | 60/60 | 58 | 240 | yes | — |
| uae-glp1 | `UAE-C23` | 2026-10-11 | after | 5 | 60/60 | 58 | 240 | yes | — |
| singapore-sglt2 | `SG-C01` | 2026-08-22 | before-v4 | 4 | 26/26 | 26 | 100 | yes | — |
| singapore-sglt2 | `SG-C02` | 2026-08-24 | before-v4 | 4 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C03` | 2026-08-26 | before-v4 | 4 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C04` | 2026-08-28 | before-v4 | 4 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C05` | 2026-08-30 | before-v4 | 4 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C06` | 2026-09-04 | before-v4 | 4 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C07` | 2026-09-06 | before-v4 | 4 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C08` | 2026-09-08 | before-v4 | 4 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C09` | 2026-09-10 | before-v4 | 4 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C10` | 2026-09-13 | before-v4 | 4 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C11` | 2026-09-15 | before-v4 | 4 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C12` | 2026-09-17 | before-v4 | 4 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C13` | 2026-09-19 | before-v4 | 4 | 26/26 | 26 | 103 | yes | — |
| singapore-sglt2 | `SG-C14` | 2026-09-21 | before-v4 | 4 | 26/26 | 26 | 103 | yes | — |
| singapore-sglt2 | `SG-C15` | 2026-09-26 | before-v4 | 4 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C16` | 2026-09-27 | before-v5 | 5 | 17/26 | 17 | 68 | **no** | captures for 17 of 26 prompts (< 95%); 17 prompts match the first cycle (< 26) |
| singapore-sglt2 | `SG-C17` | 2026-10-02 | during | 5 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C18` | 2026-10-05 | after | 5 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C19` | 2026-10-06 | after | 5 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C20` | 2026-10-07 | after | 5 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C21` | 2026-10-08 | after | 5 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C22` | 2026-10-09 | after | 5 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C23` | 2026-10-10 | after | 5 | 26/26 | 26 | 104 | yes | — |
| singapore-sglt2 | `SG-C24` | 2026-10-11 | after | 5 | 26/26 | 26 | 104 | yes | — |

## 4. E3: investigational-agent intrusion

In-scope naming answers: **21** (retatrutide 20, cagrisema 1, orforglipron 0). Codes: status-correct 18 · status-absent 3 · status-wrong 0 · UNCODED 0. In "which medicine" questions: 15. **Clinically material (status absent or wrong, in a "which medicine" answer): 3.**

Out of scope by S1 (agent approved in the series' market on the cycle date), counted as context only: uae-glp1|orforglipron 1190 answers.

### Per engine per cycle (in-scope naming answers, by code; answers per engine per cycle in brackets)

| Series | Cycle | Date | v | Window | Perplexity | Gemini | ChatGPT | Claude |
|---|---|---|---|---|---|---|---|---|
| uae-glp1 | `UAE-C01` | 2026-08-22 | 4 | before-v4 | 0 [54] | correct 1 [60] | 0 [60] | 0 [60] |
| uae-glp1 | `UAE-C02` | 2026-08-24 | 4 | before-v4 | 0 [60] | 0 [60] | correct 2 [60] | 0 [60] |
| uae-glp1 | `UAE-C03` | 2026-08-26 | 4 | before-v4 | 0 [60] | correct 1 [60] | 0 [60] | 0 [60] |
| uae-glp1 | `UAE-C04` | 2026-08-28 | 4 | before-v4 | 0 [60] | 0 [60] | correct 1 [60] | 0 [60] |
| uae-glp1 | `UAE-C05` | 2026-08-30 | 4 | before-v4 | 0 [59] | 0 [60] | 0 [60] | correct 1 [60] |
| uae-glp1 | `UAE-C06` | 2026-09-04 | 4 | before-v4 | 0 [60] | 0 [60] | 0 [60] | 0 [60] |
| uae-glp1 | `UAE-C07` | 2026-09-09 | 4 | before-v4 | 0 [60] | 0 [60] | 0 [60] | 0 [60] |
| uae-glp1 | `UAE-C08` | 2026-09-11 | 4 | before-v4 | correct 1 [60] | correct 1 [60] | 0 [60] | 0 [60] |
| uae-glp1 | `UAE-C09` | 2026-09-14 | 4 | before-v4 | 0 [57] | 0 [59] | 0 [60] | 0 [60] |
| uae-glp1 | `UAE-C10` | 2026-09-16 | 4 | before-v4 | 0 [56] | 0 [60] | 0 [60] | 0 [60] |
| uae-glp1 | `UAE-C11` | 2026-09-21 | 4 | before-v4 | 0 [59] | 0 [60] | correct 1 [60] | 0 [60] |
| uae-glp1 | `UAE-C12` | 2026-09-23 | 4 | before-v4 | 0 [60] | 0 [60] | 0 [60] | 0 [60] |
| uae-glp1 | `UAE-C13` | 2026-09-25 | 4 | before-v4 | 0 [60] | 0 [60] | 0 [60] | absent 1 [60] |
| uae-glp1 | `UAE-C14` | 2026-09-27 | 5 | before-v5 | 0 [58] | 0 [60] | correct 1 [60] | 0 [60] |
| uae-glp1 | `UAE-C15` | 2026-09-29 | 5 | during | 0 [60] | 0 [60] | 0 [60] | 0 [60] |
| uae-glp1 | `UAE-C16` | 2026-10-04 | 5 | after | correct 1 [60] | 0 [60] | 0 [60] | 0 [60] |
| uae-glp1 | `UAE-C18` | 2026-10-06 | 5 | after | 0 [60] | 0 [60] | 0 [60] | 0 [60] |
| uae-glp1 | `UAE-C19` | 2026-10-07 | 5 | after | 0 [60] | 0 [60] | 0 [60] | correct 1 [60] |
| uae-glp1 | `UAE-C20` | 2026-10-08 | 5 | after | absent 1 [60] | 0 [60] | 0 [60] | correct 1 [60] |
| uae-glp1 | `UAE-C21` | 2026-10-09 | 5 | after | 0 [60] | 0 [60] | 0 [60] | 0 [60] |
| uae-glp1 | `UAE-C22` | 2026-10-10 | 5 | after | correct 1 [60] | correct 1 [60] | 0 [60] | correct 1 [60] |
| uae-glp1 | `UAE-C23` | 2026-10-11 | 5 | after | correct 1, absent 1 [60] | 0 [60] | 0 [60] | correct 1 [60] |
| singapore-sglt2 | `SG-C01` | 2026-08-22 | 4 | before-v4 | 0 [22] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C02` | 2026-08-24 | 4 | before-v4 | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C03` | 2026-08-26 | 4 | before-v4 | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C04` | 2026-08-28 | 4 | before-v4 | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C05` | 2026-08-30 | 4 | before-v4 | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C06` | 2026-09-04 | 4 | before-v4 | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C07` | 2026-09-06 | 4 | before-v4 | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C08` | 2026-09-08 | 4 | before-v4 | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C09` | 2026-09-10 | 4 | before-v4 | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C10` | 2026-09-13 | 4 | before-v4 | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C11` | 2026-09-15 | 4 | before-v4 | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C12` | 2026-09-17 | 4 | before-v4 | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C13` | 2026-09-19 | 4 | before-v4 | 0 [26] | 0 [25] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C14` | 2026-09-21 | 4 | before-v4 | 0 [25] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C15` | 2026-09-26 | 4 | before-v4 | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C17` | 2026-10-02 | 5 | during | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C18` | 2026-10-05 | 5 | after | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C19` | 2026-10-06 | 5 | after | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C20` | 2026-10-07 | 5 | after | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C21` | 2026-10-08 | 5 | after | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C22` | 2026-10-09 | 5 | after | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C23` | 2026-10-10 | 5 | after | 0 [26] | 0 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C24` | 2026-10-11 | 5 | after | 0 [26] | 0 [26] | 0 [26] | 0 [26] |

### Ledger

| Cycle | Date | v | Engine | prompt_id | Which-medicine Q | Agent | Market status | Code | Qualifying span | Note |
|---|---|---|---|---|---|---|---|---|---|---|
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-q07 | no | retatrutide | not approved (record as of 2026-10-02) | **status-correct** | [Gemini answer text withheld] | — |
| `UAE-C02` | 2026-08-24 | 4 | ChatGPT | uae-q04 | yes | retatrutide | not approved (record as of 2026-10-02) | **status-correct** | "An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. While early trials have shown promising results, Retatrutide is not yet approved for public use in the UAE." | Listed as one of five 'alternatives to Mounjaro', with its status stated (ambiguity A3). |
| `UAE-C02` | 2026-08-24 | 4 | ChatGPT | uae-q12 | yes | retatrutide | not approved (record as of 2026-10-02) | **status-correct** | "including Retatrutide, which remains under clinical investigation and is not authorized for use in the UAE." | — |
| `UAE-C03` | 2026-08-26 | 4 | Gemini | uae-q07 | no | retatrutide | not approved (record as of 2026-10-02) | **status-correct** | [Gemini answer text withheld] | — |
| `UAE-C04` | 2026-08-28 | 4 | ChatGPT | uae-q04 | yes | retatrutide | not approved (record as of 2026-10-02) | **status-correct** | "An investigational triple agonist … Retatrutide is currently under study and not yet approved for public use in the UAE. It is not legally available for prescription or purchase." | Listed as an 'alternative to Mounjaro', with its status stated (ambiguity A3). |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-q12 | yes | retatrutide | not approved (record as of 2026-10-02) | **status-correct** | "Retatrutide, an experimental injectable treatment for weight loss, … remains under clinical investigation and has not been approved by the Emirates Drug Establishment for marketing or medical use within the UAE." | — |
| `UAE-C08` | 2026-09-11 | 4 | Gemini | uae-q07 | no | retatrutide | not approved (record as of 2026-10-02) | **status-correct** | [Gemini answer text withheld] | Correct for retatrutide; the same sentence lumps EDE-registered Ozempic and Mounjaro with it as unapproved (ambiguity A4: a status error about an APPROVED product is outside E3). |
| `UAE-C08` | 2026-09-11 | 4 | Perplexity | uae-q11 | no | retatrutide | not approved (record as of 2026-10-02) | **status-correct** | "Retatrutide has been reported as still in clinical-trial stage and not approved for use or distribution in the UAE." | — |
| `UAE-C11` | 2026-09-21 | 4 | ChatGPT | uae-q12 | yes | retatrutide | not approved (record as of 2026-10-02) | **status-correct** | "peptide-based treatments like Retatrutide, which remain under clinical investigation and are not authorized for use in the UAE." | — |
| `UAE-C13` | 2026-09-25 | 4 | Claude | uae-f03 | yes | cagrisema | not approved (record as of 2026-10-02) | **status-absent** | "A trial showed Novo's next-generation weight-loss drug CagriSema failed to match Lilly's Zepbound's efficacy." | 'Next-generation drug' and 'a trial showed' imply development but state no status (S3; ambiguity A2). Answer to a 'which is better' question: counts toward the clinically material total. Named as a comparator, not offered as an option. |
| `UAE-C14` | 2026-09-27 | 5 | ChatGPT | uae-q12 | yes | retatrutide | not approved (record as of 2026-10-02) | **status-correct** | "enforcement actions against unapproved weight-loss products, including peptide-based supplements like Retatrutide, which lack established safety profiles" | Status stated ('unapproved'); the answer calls the agent a 'supplement' (ambiguity A5: correct status, wrong product class). |
| `UAE-C16` | 2026-10-04 | 5 | Perplexity | uae-q15 | no | retatrutide | not approved as of 2026-10-02; later status not established (provisional) | **status-correct** | "proved by the EDE.[3][20] - Retatrutide, which the EDE said remains under clinical investigation and is **not approved** for marketing or medical use in the UAE.[3][20] If you mean **non-prescription" | — |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q12 | yes | retatrutide | not approved as of 2026-10-02; later status not established (provisional) | **status-correct** | "online, including Retatrutide, a weight-loss injection that has not been approved for use or distribution in the UAE - Specialists have warned against purchasing weight-loss medicines through soci" | Named only to warn against buying it. |
| `UAE-C20` | 2026-10-08 | 5 | Perplexity | uae-q23 | yes | retatrutide | not approved as of 2026-10-02; later status not established (provisional) | **status-absent** | "e, compounded GLP-1 products, or social-media injections.** Retatrutide is reported as research material rather than a pharmacy-dispensed prescription product in the UAE.[1][4] - **Do not switch between Rybelsus, Ozempic, Wegovy, and Mounja" | Ambiguity A10 (new in the after window): "research material", sold outside pharmacies, and a warning not to buy it; no statement that it is investigational, in trials or unapproved, so S3 codes it absent (as A2 did for "next-generation"). Answer to a which-medicine question, so it counts toward the clinically material total although it does not offer the agent. |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q12 | yes | retatrutide | not approved as of 2026-10-02; later status not established (provisional) | **status-correct** | "Retatrutide remains in the clinical trial stage and has not been approved for use or distribution in the UAE . ## Recommendation: For UAE consumers seeking weight management with the best" | — |
| `UAE-C22` | 2026-10-10 | 5 | Perplexity | uae-q23 | yes | retatrutide | not approved as of 2026-10-02; later status not established (provisional) | **status-correct** | "e, tirzepatide, retatrutide, or imported injections online; investigational products are not equivalent to pharmacy-dispensed medicines.[2][3] - Confirm the exact **dose, monthly quantity, cold-chain storage, and to" | Named only to warn against buying it; "investigational" stated. |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-q12 | yes | retatrutide | not approved as of 2026-10-02; later status not established (provisional) | **status-correct** | "The authority clarified that Retatrutide remains in the clinical trial stage and has not been approved for use or distribution in the UAE. --- ## Recommendation for UAE Consumers: **" | — |
| `UAE-C22` | 2026-10-10 | 5 | Gemini | uae-q07 | no | retatrutide | not approved as of 2026-10-02; later status not established (provisional) | **status-correct** | [Gemini answer text withheld] | — |
| `UAE-C23` | 2026-10-11 | 5 | Perplexity | uae-q23 | yes | retatrutide | not approved as of 2026-10-02; later status not established (provisional) | **status-correct** | "A valid prescription from a UAE-licensed clinician is required for these treatments, and products such as retatrutide remain investigational rather than ordinary pharmacy options.[3][4] Rybelsus, Ozempic and Wegovy all involve semaglutide b" | Named only to warn against buying it; "investigational" stated. |
| `UAE-C23` | 2026-10-11 | 5 | Perplexity | uae-q31 | yes | retatrutide | not approved as of 2026-10-02; later status not established (provisional) | **status-absent** | "**Do not treat online “peptide” products as alternatives:** Retatrutide and similar research compounds are not established UAE pharmacy treatments; use licensed pharmacies and prescribed products only.[2][3] ## UAE cost and ac" | Ambiguity A10 (as on 8 Oct, answer 95eb4702): "research compounds" that are "not established UAE pharmacy treatments", with a warning not to treat them as alternatives; no statement that it is investigational, in trials or unapproved, so S3 codes it absent. Answer to a which-medicine question, so it counts toward the clinically material total although it does not offer the agent. |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-q12 | yes | retatrutide | not approved as of 2026-10-02; later status not established (provisional) | **status-correct** | "The authority clarified that Retatrutide remains in the clinical trial stage and has not been approved for use or distribution in the UAE . --- ## Consumer Recommendation: **For the best safety profile as a UAE consum" | Named only to report the EDE warning. |

## 5. E4: clinical currency of efficacy figures (UAE medicine)

### 5a. Reference values (fixed before coding; `docs/evidence/easd-2026-e4-reference-values.json`)

- **fda-label**: FDA Prescribing Information, WEGOVY (semaglutide) injection and WEGOVY tablets, one combined label, 'Revised: 06/2026', Drugs@FDA NDA 215256 supplement 025 (identical text served as NDA 218316 supplement 007). Section 14 CLINICAL STUDIES. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
- **eu-smpc**: EMA Wegovy EPAR product information (SmPC, injection and tablet), section 5.1. EMA medicines dataset (timestamp 2026-10-02) lists Wegovy EMEA/H/C/005422 Authorised, latest EC decision 16/09/2026, last updated 21/09/2026. https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
- **uae-label**: NOT REACHABLE. The Emirates Drug Establishment directory lists nine Wegovy presentations (injection 0.25–2.4 mg, registered 14 Nov 2022; tablets 1.5/4/9/25 mg, registered 04 May 2026) but publishes no label or leaflet on the product detail page. No UAE label value is used. https://services.ede.gov.ae/drugdirectory/Products/Details/16052?lang=en
- **pubmed**: PubMed abstracts of the primary publications, fetched through NCBI E-utilities efetch (rettype=abstract). https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&rettype=abstract&retmode=text&id=33567185,33667417,33625476,33755728,36216945,35131037,35015037,36322838,37952131,37622681,37385278,40934115,40961952,40961953,40353578
- **novo-octane-2026-09-30**: Novo Nordisk press release, 'Plainsboro, NJ and Bagsværd, Denmark, 30 September 2026': OCTANE real-world data 'presented during a short oral session at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, on September 30, 2026.' NOT in the protocol §3 readout set; recorded here as an E4 congress-window figure only (see ledger, scheme decision S7). https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=917136

| id | Category | Trial | Dose | Measure | Value | Estimand | Timepoint | Quote |
|---|---|---|---|---|---|---|---|---|
| L-STEP1-pct | label | STEP 1 (FDA 'Study 2') | 2.4 mg SC | weight-pct | 14.9 | treatment policy | 68 wk | Table 8 … Study 2 … % change from baseline (LSMean) … PLACEBO -2.4 WEGOVY -14.9 |
| L-STEP2-pct | label | STEP 2 (FDA 'Study 3', T2D) | 2.4 mg SC | weight-pct | 9.6 | treatment policy | 68 wk | Table 8 … Study 3 … -3.4 -9.6 |
| L-STEP3-pct | label | STEP 3 (FDA 'Study 4') | 2.4 mg SC | weight-pct | 16 | treatment policy | 68 wk | Table 8 … Study 4 … -5.7 -16 |
| L-STEP4-pct | label | STEP 4 (FDA 'Study 5', from wk 20) | 2.4 mg SC | weight-pct | 7.9 | treatment policy | wk 20–68 | Table 9 … % change from Week 20 at Week 68 (LSMean) 6.9 -7.9 |
| L-STEP6-2.4-pct | label | STEP 6 (FDA 'Study 6', East Asian) | 2.4 mg SC | weight-pct | 13.2 | treatment policy | 68 wk | Table 10 … % change from baseline (LSMean) -2.1 -9.6 -13.2 |
| L-STEP6-1.7-pct | label | STEP 6 (FDA 'Study 6', East Asian) | 1.7 mg SC | weight-pct | 9.6 | treatment policy | 68 wk | Table 10 … -9.6 (WEGOVY 1.7 mg) |
| L-OASIS4-pct | label | OASIS 4 (FDA 'Study 7') | 25 mg oral | weight-pct | 13.6 | treatment policy | 64 wk | Table 11 … % change from baseline (LSMean) -2.4 -13.6 |
| L-STEPUP-7.2-pct-fda | label | STEP UP (FDA 'Study 8') | 7.2 mg SC | weight-pct | 18.8 | treatment policy | 72 wk | Table 12 … % change from baseline (LSMean) -3.9 -15.5 -18.8 |
| L-STEPUP-2.4-pct-fda | label | STEP UP (FDA 'Study 8') | 2.4 mg SC | weight-pct | 15.5 | treatment policy | 72 wk | Table 12 … -15.5 (WEGOVY 2.4 mg) |
| L-STEPUPT2D-7.2-pct | label | STEP UP T2D (FDA 'Study 9') | 7.2 mg SC | weight-pct | 13.2 | treatment policy | 72 wk | Table 12 … Study 9 … -3.8 -10.4 -13.2 |
| L-STEPUPT2D-2.4-pct | label | STEP UP T2D (FDA 'Study 9') | 2.4 mg SC | weight-pct | 10.4 | treatment policy | 72 wk | Table 12 … -10.4 (WEGOVY 2.4 mg) |
| L-SELECT-pct | label | SELECT (FDA 'Study 1') | 2.4 mg SC | weight-pct | 9.43 | LSMean | 104 wk | Table 7 … Body Weight … -0.93 … -9.43 … -8.53 (footnote 3: unit is percentage change from baseline) |
| L-TEENS-bmi-pct | label | STEP TEENS (FDA 14.3) | 2.4 mg SC | weight-pct | 16.1 | treatment policy | 68 wk | Table 18 … % change from baseline in BMI (LSMean) 0.6 -16.1 |
| L-TEENS-wt-pct | label | STEP TEENS (FDA 14.3) | 2.4 mg SC | weight-pct | 14.7 | treatment policy | 68 wk | Table 18 … Body Weight … % change from baseline (LSMean) 2.7 -14.7 |
| L-STEP2-hba1c | label | STEP 2 (FDA 'Study 3', T2D) | 2.4 mg SC | hba1c-pp | 1.6 | LSMean | 68 wk | Table 13 … HbA1c (%) … Changes from baseline (LSMean) … -0.4 -1.6 |
| L-STEPUPT2D-7.2-hba1c | label | STEP UP T2D (FDA 'Study 9') | 7.2 mg SC | hba1c-pp | 1.7 | LSMean | 72 wk | Table 17 … HbA1c (%) … Changes from baseline (LSMean1) … -0.2 -1.6 -1.7 |
| L-STEP6-hba1c | label | STEP 6 | 1.7 / 2.4 mg SC | hba1c-pp | 0.9 | LSMean | 68 wk | Table 15 … HbA1c (%) … Change from baseline (LSMean1) 0 -0.9 -0.9 |
| L-SELECT-hba1c | label | SELECT | 2.4 mg SC | hba1c-pp | 0.3 | LSMean | 104 wk | Table 7 … HbA1c (%) 5.8 0 5.8 -0.3 -0.3 |
| E-STEP1-kg | label | STEP 1 | 2.4 mg SC | weight-kg | 15.3 | treatment policy | 68 wk | Table 4 STEP 1 … Change (kg) from baseline -15.3 -2.6 |
| E-STEP1-tp | label | STEP 1 | 2.4 mg SC | weight-pct | 16.9 | trial product (on treatment) | 68 wk | the estimated changes from randomisation to week 68 for body weight … were -16.9% and -2.4% |
| E-STEP2-kg | label | STEP 2 | 2.4 mg SC | weight-kg | 9.7 | treatment policy | 68 wk | Table 5 STEP 2 … Change (kg) from baseline -9.7 -3.5 |
| E-STEP2-tp | label | STEP 2 | 2.4 mg SC | weight-pct | 10.6 | trial product | 68 wk | … were -10.6% and -3.1% for semaglutide 2.4 mg and placebo |
| E-STEP2-hba1c-mmol | label | STEP 2 | 2.4 mg SC | hba1c-pp | 1.6 | treatment policy | 68 wk | HbA1c (mmol/mol (%)) Change from baseline -17.5 (-1.6) -4.1 (-0.4) |
| E-STEP3-kg | label | STEP 3 | 2.4 mg SC | weight-kg | 16.8 | treatment policy | 68 wk | Table 6 STEP 3 … Change (kg) from baseline -16.8 -6.2 |
| E-STEP3-tp | label | STEP 3 | 2.4 mg SC | weight-pct | 17.6 | trial product | 68 wk | … were -17.6% and -5.0% for semaglutide 2.4 mg |
| E-STEP4-kg | label | STEP 4 | 2.4 mg SC | weight-kg | 7.1 | treatment policy | wk 20–68 | Table 7 STEP 4 … Change (kg) from baseline -7.1 6.1 |
| E-STEP4-tp | label | STEP 4 | 2.4 mg SC | weight-pct | 8.8 | trial product | wk 20–68 | … were -8.8% and 6.5% for semaglutide 2.4 mg |
| E-STEP5-pct | label | STEP 5 | 2.4 mg SC | weight-pct | 15.2 | treatment policy | 104 wk | Table 8 STEP 5: Results at week 104 … Change (%) from baseline -15.2 -2.6 |
| E-STEP5-kg | label | STEP 5 | 2.4 mg SC | weight-kg | 16.1 | treatment policy | 104 wk | Change (kg) from baseline -16.1 -3.2 |
| E-STEP5-tp | label | STEP 5 | 2.4 mg SC | weight-pct | 16.7 | trial product | 104 wk | … were -16.7% and -0.6% for semaglutide and placebo |
| E-STEP8-pct | label | STEP 8 (vs liraglutide) | 2.4 mg SC | weight-pct | 15.8 | treatment policy | 68 wk | Table 9 STEP 8 … Change (%) from baseline -15.8 -6.4 |
| E-STEP8-kg | label | STEP 8 | 2.4 mg SC | weight-kg | 15.3 | treatment policy | 68 wk | Change (kg) from baseline -15.3 -6.8 |
| E-STEP8-tp | label | STEP 8 | 2.4 mg SC | weight-pct | 16.7 | trial product | 68 wk | … were -16.7% and -6.7% for semaglutide 2.4 mg and liraglutide 3 mg |
| E-STEP9-pct | label | STEP 9 (knee OA) | 2.4 mg SC | weight-pct | 13.7 | treatment policy | 68 wk | Table 10 STEP 9 … Change (%) from baseline -13.7 -3.2 |
| E-STEP9-tp | label | STEP 9 (knee OA) | 2.4 mg SC | weight-pct | 14.5 | trial product | 68 wk | … the estimated changes from baseline to week 68 for body weight were -14.5% |
| E-STEPUP-7.2-pct | label | STEP UP | 7.2 mg SC | weight-pct | 18.7 | treatment policy | 72 wk | Table 11 … Change (%) from baseline -18.7 -15.6 -3.9 |
| E-STEPUP-2.4-pct | label | STEP UP | 2.4 mg SC | weight-pct | 15.6 | treatment policy | 72 wk | Table 11 … -15.6 (2.4 mg) |
| E-STEPUP-7.2-tp | label | STEP UP | 7.2 mg SC | weight-pct | 20.7 | trial product | 72 wk | Change (%) from baseline Trial product estimand -20.7 -17.5 -2.4 |
| E-STEPUP-2.4-tp | label | STEP UP | 2.4 mg SC | weight-pct | 17.5 | trial product | 72 wk | … -17.5 (2.4 mg, trial product estimand) |
| E-STEPUP-7.2-kg | label | STEP UP | 7.2 mg SC | weight-kg | 20.9 | treatment policy | 72 wk | Change (kg) from baseline -20.9 -17.3 -4.6 |
| E-STEPUP-2.4-kg | label | STEP UP | 2.4 mg SC | weight-kg | 17.3 | treatment policy | 72 wk | Change (kg) from baseline … -17.3 (2.4 mg) |
| E-STEPUPT2D-7.2-tp | label | STEP UP T2D | 7.2 mg SC | weight-pct | 14.1 | trial product | 72 wk | Trial product estimand … -14.1 -3.6 |
| E-STEPUPT2D-7.2-kg | label | STEP UP T2D | 7.2 mg SC | weight-kg | 14.5 | treatment policy | 72 wk | Change (kg) from baseline … -14.5 -4.3 |
| E-TEENS-kg | label | STEP TEENS | 2.4 mg SC | weight-kg | 15.3 | treatment policy | 68 wk | Table 13 STEP TEENS … Body Weight … Change (kg) from baseline -15.3 2.4 |
| E-TEENS-bmi-tp | label | STEP TEENS | 2.4 mg SC | weight-pct | 17.9 | trial product | 68 wk | … for BMI … were -17.9% and 0.6% |
| E-OASIS4-kg | label | OASIS 4 | 25 mg oral | weight-kg | 14.2 | treatment policy | 64 wk | Table 2 OASIS 4 … Change (kg) from baseline -14.2 -2.2 |
| E-OASIS4-tp | label | OASIS 4 | 25 mg oral | weight-pct | 16.6 | trial product | 64 wk | … were -16.6% and -2.8% for oral semaglutide 25 mg and placebo |
| P-STEP-HFpEF-pct | published | STEP-HFpEF (PMID 37622681, NEJM 2023) | 2.4 mg SC | weight-pct | 13.3 | treatment policy | not stated in the abstract | the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo |
| P-OASIS1-pct | published | OASIS 1 (PMID 37385278, Lancet 2023) | 50 mg oral (not a marketed dose) | weight-pct | 15.1 | treatment policy | 68 wk | The estimated mean bodyweight change from baseline to week 68 was -15·1% (SE 0·5) with oral semaglutide 50 mg |
| P-SURMOUNT5-sema-pct | published | SURMOUNT-5 (PMID 40353578, NEJM 2025), semaglutide arm | 2.4 mg SC (MTD) | weight-pct | 13.7 | LSMean | 72 wk | -20.2% … with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide |
| P-STEP4-runin-pct | published | STEP 4 run-in (PMID 33755728, JAMA 2021) | 2.4 mg SC | weight-pct | 10.6 | observed | wk 0–20 | completed the 20-week run-in period (with a mean weight loss of 10.6%) |
| C-OCTANE-pct | congress | OCTANE real-world switch cohort (EASD 2026, 30 Sep) | oral 25 mg after injectable | weight-pct | 4.1 | observed | 3 months | Average weight loss: 4.1% body weight or 4.0 kg (8.8 lbs) in three months |
| C-OCTANE-kg | congress | OCTANE (EASD 2026, 30 Sep) | oral 25 mg after injectable | weight-kg | 4 | observed | 3 months | 4.1% body weight or 4.0 kg (8.8 lbs) in three months |

### 5b. Outcomes

Answers with ≥ 1 coded figure: **712**. Answer outcome (S8): label 623 · published 0 · no-source 87 · congress 2. Figures: 1241 (label 1147, published 0, no-source 92, congress 2); by precision decimal 376, integer 856, converted 9; decimal-precision figures by category label 370, published 0, no-source 4, congress 2. Figures excluded by rule S5: 160.

| Series | Cycle | Date | v | Window | Perplexity | Gemini | ChatGPT | Claude |
|---|---|---|---|---|---|---|---|---|
| uae-glp1 | `UAE-C01` | 2026-08-22 | 4 | before-v4 | label 3 [54] | label 8, no-source 4 [60] | label 6 [60] | label 9, no-source 1 [60] |
| uae-glp1 | `UAE-C02` | 2026-08-24 | 4 | before-v4 | label 3 [60] | label 8, no-source 3 [60] | label 8 [60] | label 8, no-source 2 [60] |
| uae-glp1 | `UAE-C03` | 2026-08-26 | 4 | before-v4 | label 1, no-source 1 [60] | label 7, no-source 2 [60] | label 4 [60] | label 9, no-source 3 [60] |
| uae-glp1 | `UAE-C04` | 2026-08-28 | 4 | before-v4 | label 1 [60] | label 12, no-source 2 [60] | label 8 [60] | label 4, no-source 4 [60] |
| uae-glp1 | `UAE-C05` | 2026-08-30 | 4 | before-v4 | label 1 [59] | label 6, no-source 5 [60] | label 5 [60] | label 10, no-source 2 [60] |
| uae-glp1 | `UAE-C06` | 2026-09-04 | 4 | before-v4 | label 6 [60] | label 9, no-source 1 [60] | label 7 [60] | label 13, no-source 1 [60] |
| uae-glp1 | `UAE-C07` | 2026-09-09 | 4 | before-v4 | label 5 [60] | label 6, no-source 2 [60] | label 10 [60] | label 6, no-source 2 [60] |
| uae-glp1 | `UAE-C08` | 2026-09-11 | 4 | before-v4 | label 4 [60] | label 7, no-source 4 [60] | label 7 [60] | label 8, no-source 3 [60] |
| uae-glp1 | `UAE-C09` | 2026-09-14 | 4 | before-v4 | label 4 [57] | label 6, no-source 2 [59] | label 4 [60] | label 7, no-source 3 [60] |
| uae-glp1 | `UAE-C10` | 2026-09-16 | 4 | before-v4 | label 3 [56] | label 8, no-source 1 [60] | label 5 [60] | label 10, no-source 1 [60] |
| uae-glp1 | `UAE-C11` | 2026-09-21 | 4 | before-v4 | label 1 [59] | label 8, no-source 2 [60] | label 6 [60] | label 8, no-source 3 [60] |
| uae-glp1 | `UAE-C12` | 2026-09-23 | 4 | before-v4 | label 3 [60] | label 9, no-source 3 [60] | label 3 [60] | label 7, no-source 2 [60] |
| uae-glp1 | `UAE-C13` | 2026-09-25 | 4 | before-v4 | label 6 [60] | label 6 [60] | label 7 [60] | label 5, no-source 3 [60] |
| uae-glp1 | `UAE-C14` | 2026-09-27 | 5 | before-v5 | label 4 [58] | label 10, no-source 1 [60] | label 6 [60] | label 8, no-source 1 [60] |
| uae-glp1 | `UAE-C15` | 2026-09-29 | 5 | during | 0 [60] | label 11, no-source 1 [60] | label 6 [60] | label 9, no-source 2 [60] |
| uae-glp1 | `UAE-C16` | 2026-10-04 | 5 | after | label 3 [60] | label 8, no-source 2 [60] | label 6 [60] | label 15, no-source 1 [60] |
| uae-glp1 | `UAE-C18` | 2026-10-06 | 5 | after | label 2 [60] | label 8, no-source 1, congress 1 [60] | label 6 [60] | label 15, no-source 1 [60] |
| uae-glp1 | `UAE-C19` | 2026-10-07 | 5 | after | label 6, no-source 1 [60] | label 5, no-source 2, congress 1 [60] | label 7 [60] | label 17 [60] |
| uae-glp1 | `UAE-C20` | 2026-10-08 | 5 | after | label 8 [60] | label 10 [60] | label 8 [60] | label 18, no-source 2 [60] |
| uae-glp1 | `UAE-C21` | 2026-10-09 | 5 | after | label 6, no-source 2 [60] | label 11 [60] | label 5 [60] | label 16 [60] |
| uae-glp1 | `UAE-C22` | 2026-10-10 | 5 | after | label 7 [60] | label 7, no-source 4 [60] | label 4 [60] | label 12, no-source 1 [60] |
| uae-glp1 | `UAE-C23` | 2026-10-11 | 5 | after | label 6 [60] | label 8, no-source 1 [60] | label 6 [60] | label 14, no-source 2 [60] |

### 5c. Ledger (one row per answer)

| Cycle | Date | v | Engine | prompt_id | Outcome | Figures (value → category [refs]) |
|---|---|---|---|---|---|---|
| `UAE-C01` | 2026-08-22 | 4 | ChatGPT | uae-q05 | **label** | "…ce excess body weight and maintain weight reduction long-term, with a mean weight loss of 17%.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-q28 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C01` | 2026-08-22 | 4 | ChatGPT | uae-f05 | **label** | "…In the STEP-1 trial, participants using Wegovy experienced an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C01` | 2026-08-22 | 4 | ChatGPT | uae-f01 | **label** | "…- Efficacy: Clinical studies have demonstrated an average weight loss of approximately 15% of initial body weight over 68 weeks when combine…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C01` | 2026-08-22 | 4 | ChatGPT | uae-f06 | **label** | "…al studies have demonstrated that Wegovy® can lead to a mean weight loss of approximately 17% in adults with obesity or overweight conditions.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C01` | 2026-08-22 | 4 | ChatGPT | uae-q31 | **label** | "…Clinical trials have demonstrated an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C01` | 2026-08-22 | 4 | ChatGPT | uae-f04 | **label** | "…cal studies have demonstrated that Wegovy can lead to a mean weight loss of approximately 17% in adults with obesity or overweight conditions.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C01` | 2026-08-22 | 4 | Claude | uae-f05 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C01` | 2026-08-22 | 4 | Claude | uae-f01 | **label** | "…inical trials (OASIS 4) showed that the once-daily 25 mg Wegovy pill delivered an average 17% weight loss, comparable to the injectable version…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…oral Wegovy reduces body weight by up to 16.6% compared to Foundayo's 12.4%…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C01` | 2026-08-22 | 4 | Claude | uae-q27 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 percent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C01` | 2026-08-22 | 4 | Claude | uae-q14 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C01` | 2026-08-22 | 4 | Claude | uae-q23 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C01` | 2026-08-22 | 4 | Claude | uae-f02 | **no-source** | "…20% weight loss over six months at the top dose, and Wegovy (semaglutide) achieves around 12 to 15% weight loss over 12 months when paired with lifes…" 12% → no-source; "…20% weight loss over six months at the top dose, and Wegovy (semaglutide) achieves around 12 to 15% weight loss over 12 months when paired with lifes…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…the once-daily 25 mg Wegovy pill delivered an average 17% weight loss, comparable to the injectable version…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C01` | 2026-08-22 | 4 | Claude | uae-q29 | **label** | "…ight with Wegovy compared to Saxenda—in a 68-week study, people taking Wegovy lost nearly 16% of their starting weight on average, compared to…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C01` | 2026-08-22 | 4 | Claude | uae-f06 | **label** | "…Injectable GLP-1 therapies show oral Wegovy reducing body weight by up to 16.6% compared to Foundayo's 12.4%…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-f01 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct] |
| `UAE-C01` | 2026-08-22 | 4 | Claude | uae-f03 | **label** | "…linical trial (OASIS 4) showed that the once-daily 25 mg Wegovy pill delivered an average 17% weight loss, comparable to the injectable version…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-f02 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP8-pct] |
| `UAE-C01` | 2026-08-22 | 4 | Perplexity | uae-f06 | **label** | "…oducing lower average weight loss than Wegovy, with Saxenda around 5–8% and Wegovy around 15–17%.[12]…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…oducing lower average weight loss than Wegovy, with Saxenda around 5–8% and Wegovy around 15–17%.[12]…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-q23 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-q04 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-q29 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C01` | 2026-08-22 | 4 | Claude | uae-q20 | **label** | "…In studies, Wegovy pills (semaglutide) showed an average weight loss of 14%, while Foundayo (orforglipron) showed an average…" 14% → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C01` | 2026-08-22 | 4 | Perplexity | uae-q32 | **label** | "…ed in a PCOS weight-management programme and cites STEP-trial average weight reduction of 14.9% over 68 weeks.[3] \| Stronger weight-loss effect,…" 14.9% → label [L-STEP1-pct] |
| `UAE-C01` | 2026-08-22 | 4 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct] |
| `UAE-C01` | 2026-08-22 | 4 | Perplexity | uae-q25 | **label** | "…are: UAE providers market GLP-1/GIP treatments using trial-based benchmarks such as up to 15% body-weight loss with semaglutide-class therapy a…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C02` | 2026-08-24 | 4 | ChatGPT | uae-q19 | **label** | "…Clinical trials have shown an average weight loss of 15% over 68 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C02` | 2026-08-24 | 4 | ChatGPT | uae-q04 | **label** | "…udies have demonstrated that Wegovy can result in an average weight loss of approximately 15% over 68 weeks when combined with lifestyle suppor…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C02` | 2026-08-24 | 4 | ChatGPT | uae-f05 | **label** | "…In the STEP-1 trial, participants using Wegovy experienced an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C02` | 2026-08-24 | 4 | ChatGPT | uae-q23 | **label** | "…available as a weekly injection, Wegovy has demonstrated an average weight loss of around 15% over 68 weeks in clinical studies.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C02` | 2026-08-24 | 4 | ChatGPT | uae-f01 | **label** | "…studies have demonstrated that Wegovy can lead to an average weight loss of approximately 15% of initial body weight over 68 weeks when combine…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C02` | 2026-08-24 | 4 | ChatGPT | uae-f06 | **label** | "…- Wegovy®: Clinical trials have demonstrated a mean weight loss of approximately 17% in adults with obesity or overweight conditions w…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C02` | 2026-08-24 | 4 | ChatGPT | uae-q29 | **label** | "…Clinical studies indicate an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C02` | 2026-08-24 | 4 | Claude | uae-f01 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C02` | 2026-08-24 | 4 | Claude | uae-f04 | **no-source** | "…clinical studies show patients lost about 33 lbs on average—roughly 14% of body weight—comparable…" 15kg(conv) → label [E-STEP1-kg, E-STEP8-kg, E-STEPUPT2D-7.2-kg, …]; "…clinical studies show patients lost about 33 lbs on average—roughly 14% of body weight—comparable to the injection withou…" 14% → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; "…ows around 20% weight loss over six months at top dose, while injectable Wegovy is around 12-15% over 12 months—new pills sit slightly below injec…" 12% → no-source; "…ows around 20% weight loss over six months at top dose, while injectable Wegovy is around 12-15% over 12 months—new pills sit slightly below injec…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C02` | 2026-08-24 | 4 | Claude | uae-f05 | **label** | "…oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C02` | 2026-08-24 | 4 | Claude | uae-q04 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp]; "…Oral Wegovy reduces body weight by up to 16.6 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C02` | 2026-08-24 | 4 | Claude | uae-q31 | **label** | "…In clinical trials, semaglutide 2.4mg delivered an average of 15–17% body weight loss over 68 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…In clinical trials, semaglutide 2.4mg delivered an average of 15–17% body weight loss over 68 weeks.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6% compared to Foundayo's 12.4%.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C02` | 2026-08-24 | 4 | Claude | uae-f02 | **no-source** | "…round 20% weight loss over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…round 20% weight loss over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C02` | 2026-08-24 | 4 | Claude | uae-q27 | **label** | "…t alternative to Zepbound is Wegovy (semaglutide), another injectable GLP-1 that produces 15% average body weight loss.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6% compared to Foundayo's 12.4%, and oral pills cost…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C02` | 2026-08-24 | 4 | Claude | uae-f06 | **label** | "…Patients who took Saxenda lost 6.4% of their body weight over 68 weeks, compared to 15.8% with Wegovy…" 15.8% → label [E-STEP8-pct]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C02` | 2026-08-24 | 4 | Gemini | uae-f01 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C02` | 2026-08-24 | 4 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C02` | 2026-08-24 | 4 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp] |
| `UAE-C02` | 2026-08-24 | 4 | Gemini | uae-q31 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C02` | 2026-08-24 | 4 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C02` | 2026-08-24 | 4 | Perplexity | uae-f04 | **label** | "…has solid weight-loss results: UAE reporting and trial summaries put average loss around 15% to 17% over roughly a year when taken properly.[2][3][7]…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…has solid weight-loss results: UAE reporting and trial summaries put average loss around 15% to 17% over roughly a year when taken properly.[2][3][7]…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C02` | 2026-08-24 | 4 | Gemini | uae-q23 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C02` | 2026-08-24 | 4 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct] |
| `UAE-C02` | 2026-08-24 | 4 | Perplexity | uae-f06 | **label** | "…as producing more weight loss than Saxenda, with Saxenda around 5–8% versus Wegovy around 15–17% in cited summaries.[13]…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…as producing more weight loss than Saxenda, with Saxenda around 5–8% versus Wegovy around 15–17% in cited summaries.[13]…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C02` | 2026-08-24 | 4 | Gemini | uae-f06 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C02` | 2026-08-24 | 4 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C02` | 2026-08-24 | 4 | Gemini | uae-q04 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C02` | 2026-08-24 | 4 | ChatGPT | uae-q06 | **label** | "…trials have shown that a 25 mg daily dose of oral semaglutide resulted in an approximate 17% mean weight loss among adults with obesity or ove…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C02` | 2026-08-24 | 4 | Claude | uae-q13 | **label** | "…GLP-1 therapies remaining more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C02` | 2026-08-24 | 4 | Claude | uae-q06 | **label** | "…Semaglutide closely follows, with averages of up to 15–21% weight loss with certain formulations and doses…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Semaglutide closely follows, with averages of up to 15–21% weight loss with certain formulations and doses…" 21% → label [E-STEPUP-7.2-tp]; "…Semaglutide injected weekly reduced body weight by around 11% after 24 to 68 weeks, with effects likely sustain…" 11% → label [E-STEP2-tp] |
| `UAE-C02` | 2026-08-24 | 4 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct] |
| `UAE-C02` | 2026-08-24 | 4 | Perplexity | uae-q20 | **label** | "…trials show tirzepatide produced up to 22.5% average body-weight loss at 72 weeks, versus 15% with semaglutide, which indicates stronger effica…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C03` | 2026-08-26 | 4 | Claude | uae-q18 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C03` | 2026-08-26 | 4 | ChatGPT | uae-f05 | **label** | "…Wegovy has demonstrated a mean weight loss of approximately 14.9% over 68 weeks in clinical trials.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C03` | 2026-08-26 | 4 | ChatGPT | uae-q27 | **label** | "…-weekly injectable GLP-1 receptor agonist that has demonstrated an average weight loss of 14.9% over 68 weeks in clinical studies.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C03` | 2026-08-26 | 4 | ChatGPT | uae-f02 | **label** | "…trials have demonstrated that Wegovy can lead to an average weight loss of approximately 15% of body weight over 68–72 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C03` | 2026-08-26 | 4 | ChatGPT | uae-f01 | **label** | "…linical trials have demonstrated that Wegovy leads to a mean weight loss of approximately 17%, with additional benefits in reducing the risk of…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C03` | 2026-08-26 | 4 | Claude | uae-f01 | **label** | "…linical trial (OASIS 4) showed that the once-daily 25 mg Wegovy pill delivered an average 17% weight loss, comparable to the injectable version…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C03` | 2026-08-26 | 4 | Claude | uae-f05 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C03` | 2026-08-26 | 4 | Claude | uae-q23 | **no-source** | "…Wegovy achieves around 12 to 15% weight loss over 12 months when paired with lifes…" 12% → no-source; "…Wegovy achieves around 12 to 15% weight loss over 12 months when paired with lifes…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Oral Wegovy reduces body weight by up to 16.6%…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C03` | 2026-08-26 | 4 | Claude | uae-f04 | **label** | "…Wegovy delivers genuine results—people taking the higher dose lose around 20.7% of total body weight on average…" 20.7% → label [E-STEPUP-7.2-tp]; "…In a 4-year study, adults maintained an average weight loss of 10%, and it lowers heart disease risk…" 10% → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; "…Injectable GLP-1s remain more effective—oral Wegovy reduces weight by up to 16.6% vs. competitors at 12.4%…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C03` | 2026-08-26 | 4 | Claude | uae-f02 | **no-source** | "…On average weight loss, Mounjaro generally outperforms Wegovy in trials (around 20% vs 12 to 15%).…" 12% → no-source; "…On average weight loss, Mounjaro generally outperforms Wegovy in trials (around 20% vs 12 to 15%).…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C03` | 2026-08-26 | 4 | Claude | uae-q31 | **no-source** | "…Wegovy (semaglutide) delivers around 12-15% weight loss over 12 months when paired with lifes…" 12% → no-source; "…Wegovy (semaglutide) delivers around 12-15% weight loss over 12 months when paired with lifes…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C03` | 2026-08-26 | 4 | Claude | uae-f03 | **label** | "…(semaglutide), with Zepbound leading to superior average weight loss of 20.2% compared to 13.7% with Wegovy.…" 13.7% → label [E-STEP9-pct]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C03` | 2026-08-26 | 4 | Claude | uae-f06 | **label** | "…linical trial (OASIS 4) showed that the once-daily 25 mg Wegovy pill delivered an average 17% weight loss…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C03` | 2026-08-26 | 4 | Claude | uae-q29 | **label** | "…In a 68-week study, people taking Wegovy lost nearly 16% of their starting weight, on average, compared wi…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C03` | 2026-08-26 | 4 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C03` | 2026-08-26 | 4 | Gemini | uae-f01 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C03` | 2026-08-26 | 4 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C03` | 2026-08-26 | 4 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C03` | 2026-08-26 | 4 | Gemini | uae-f02 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C03` | 2026-08-26 | 4 | Perplexity | uae-f02 | **no-source** | "…\| Average weight loss cited in UAE sources \| About 12–15% over longer treatment periods \| About 20% at top…" 12% → no-source; "…\| Average weight loss cited in UAE sources \| About 12–15% over longer treatment periods \| About 20% at top…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C03` | 2026-08-26 | 4 | Gemini | uae-q31 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C03` | 2026-08-26 | 4 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C03` | 2026-08-26 | 4 | Claude | uae-q12 | **label** | "…GLP-1 therapies remaining more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C03` | 2026-08-26 | 4 | Claude | uae-q20 | **label** | "…Oral Wegovy led to an average 14% body weight reduction, compared with 11% for Foun…" 14% → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C03` | 2026-08-26 | 4 | Gemini | uae-q25 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C03` | 2026-08-26 | 4 | Gemini | uae-q13 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C03` | 2026-08-26 | 4 | Perplexity | uae-q25 | **label** | "…es, can produce larger losses in clinical-trial settings; one UAE clinic page cites about 15% average weight loss with Wegovy in a 68-week stud…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C04` | 2026-08-28 | 4 | Claude | uae-q21 | **no-source** | "…% average weight loss over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…% average weight loss over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C04` | 2026-08-28 | 4 | Claude | uae-q18 | **no-source** | "…Wegovy produces around 12 to 15% weight loss over 12 months when paired with lifes…" 12% → no-source; "…Wegovy produces around 12 to 15% weight loss over 12 months when paired with lifes…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-q18 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-q09 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP6-2.4-pct, L-STEPUPT2D-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C04` | 2026-08-28 | 4 | ChatGPT | uae-f04 | **label** | "…cal studies have demonstrated that Wegovy can lead to a mean weight loss of approximately 17% in adults with obesity or overweight conditions.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C04` | 2026-08-28 | 4 | ChatGPT | uae-f01 | **label** | "…ical trials have demonstrated that Wegovy can lead to a mean weight loss of approximately 17% of body weight.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C04` | 2026-08-28 | 4 | ChatGPT | uae-f02 | **label** | "…trials have demonstrated that Wegovy can lead to an average weight loss of approximately 15% of body weight over a 68-week period.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C04` | 2026-08-28 | 4 | ChatGPT | uae-q31 | **label** | "…It has demonstrated an average weight loss of 14.9% over 68 weeks in clinical trials.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C04` | 2026-08-28 | 4 | ChatGPT | uae-f06 | **label** | "…have demonstrated that oral semaglutide 25 mg taken once daily can lead to approximately 17% mean weight loss in adults with obesity or overwe…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C04` | 2026-08-28 | 4 | ChatGPT | uae-q04 | **label** | "…ed for weight management, Wegovy has demonstrated an average weight loss of approximately 14.9% over 68 weeks in clinical trials.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C04` | 2026-08-28 | 4 | ChatGPT | uae-f05 | **label** | "…trials have demonstrated that Wegovy can lead to an average weight loss of approximately 15–17% of body weight.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…trials have demonstrated that Wegovy can lead to an average weight loss of approximately 15–17% of body weight.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C04` | 2026-08-28 | 4 | ChatGPT | uae-q29 | **label** | "…al trials have shown significant weight loss results, with some participants losing up to 16.6% of their body weight.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C04` | 2026-08-28 | 4 | Claude | uae-f04 | **label** | "…Wegovy shows real results—people taking the higher dose lost on average 20.7% of their total body weight…" 20.7% → label [E-STEPUP-7.2-tp]; "…it helps people maintain weight loss long-term, with adults maintaining an average of 10% weight loss over 4 years…" 10% → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct] |
| `UAE-C04` | 2026-08-28 | 4 | Claude | uae-f05 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C04` | 2026-08-28 | 4 | Claude | uae-q29 | **label** | "…ht with Wegovy compared with Saxenda—in a 68-week study, people taking Wegovy lost nearly 16% of their starting weight, on average, compared wi…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C04` | 2026-08-28 | 4 | Claude | uae-f02 | **no-source** | "…the new Wegovy 7.2mg dose achieves approximately 20.7% weight loss, largely closing the gap.…" 20.7% → label [E-STEPUP-7.2-tp]; "…with Mounjaro sitting at around 20% over six months at the top dose, and Wegovy at around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…with Mounjaro sitting at around 20% over six months at the top dose, and Wegovy at around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…separate randomized clinical trials, mean weight loss reached up to 22.5% with Zepbound, 20.7% with Wegovy HD, 16.6% with oral Wegovy, and 11.1%…" 20.7% → label [E-STEPUP-7.2-tp]; "…linical trials, mean weight loss reached up to 22.5% with Zepbound, 20.7% with Wegovy HD, 16.6% with oral Wegovy, and 11.1% with oral…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C04` | 2026-08-28 | 4 | Claude | uae-q27 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C04` | 2026-08-28 | 4 | Claude | uae-q04 | **no-source** | "…Studies suggest an average weight loss of 15-20%…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Studies suggest an average weight loss of 15-20%…" 20% → no-source |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-f04 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-f01 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-f02 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-q31 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-q04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-q29 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-q13 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C04` | 2026-08-28 | 4 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C04` | 2026-08-28 | 4 | Perplexity | uae-q25 | **label** | "…ble in the UAE: local providers commonly cite larger losses, with some advertising around 15% average loss based on clinical trials for semaglu…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C05` | 2026-08-30 | 4 | ChatGPT | uae-f04 | **label** | "…ed its effectiveness, with participants achieving an average weight loss of approximately 17%.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C05` | 2026-08-30 | 4 | ChatGPT | uae-f05 | **label** | "…trials have demonstrated that Wegovy can lead to an average weight loss of approximately 15–17% of body weight.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…trials have demonstrated that Wegovy can lead to an average weight loss of approximately 15–17% of body weight.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C05` | 2026-08-30 | 4 | ChatGPT | uae-f02 | **label** | "…n average of 20.2% of their body weight over 72 weeks when using tirzepatide, compared to 13.7% with semaglutide.…" 13.7% → label [E-STEP9-pct]; "…wn to aid in weight loss, with clinical trials indicating an average weight loss of about 15% over 68–72 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C05` | 2026-08-30 | 4 | ChatGPT | uae-f01 | **label** | "…ical trials have demonstrated that Wegovy can lead to a mean weight loss of approximately 17% of body weight.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C05` | 2026-08-30 | 4 | ChatGPT | uae-f06 | **label** | "…t oral semaglutide 25 mg taken once daily can lead to a mean weight loss of approximately 17% in adults with obesity or overweight conditions.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-q30 | **label** | "…o and Wegovy are now available in the UAE, with oral Wegovy reducing body weight by up to 16.6%…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-f05 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-f04 | **no-source** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp]; "…ide) sits at around 20% average weight loss at the top dose, compared to Wegovy at around 12 to 15% over 12 months…" 12% → no-source; "…ide) sits at around 20% average weight loss at the top dose, compared to Wegovy at around 12 to 15% over 12 months…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-f01 | **label** | "…Clinical trials show Wegovy® patients achieve approximately 15-18% weight loss over 68 weeks, while Ozempic® results…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Clinical trials show Wegovy® patients achieve approximately 15-18% weight loss over 68 weeks, while Ozempic® results…" 18% → label [E-STEP3-tp, E-STEPUP-2.4-tp, E-TEENS-bmi-tp]; "…linical trial (OASIS 4) showed that the once-daily 25 mg Wegovy pill delivered an average 17% weight loss, comparable to the injectable version…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-q29 | **label** | "…In a 68-week study, people taking Wegovy lost nearly 16% of their starting weight, on average, compared wi…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-f02 | **label** | "…Adults with obesity who took a higher dose of Wegovy (7.2 mg) for 72 weeks lost around 21% of body weight…" 21% → label [E-STEPUP-7.2-tp] |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-q04 | **no-source** | "…alternatives for weight loss deliver comparable results, with studies showing an average 12–15% reduction in body weight…" 12% → no-source; "…alternatives for weight loss deliver comparable results, with studies showing an average 12–15% reduction in body weight…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-f06 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-q27 | **label** | "…Wegovy produces 15% average body weight loss.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-f03 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp]; "…linical trial (OASIS 4) showed that the once-daily 25 mg Wegovy pill delivered an average 17% weight loss, comparable to the injectable version…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C05` | 2026-08-30 | 4 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C05` | 2026-08-30 | 4 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C05` | 2026-08-30 | 4 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C05` | 2026-08-30 | 4 | Gemini | uae-f01 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C05` | 2026-08-30 | 4 | Gemini | uae-f04 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source |
| `UAE-C05` | 2026-08-30 | 4 | Gemini | uae-q31 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C05` | 2026-08-30 | 4 | Gemini | uae-f05 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C05` | 2026-08-30 | 4 | Perplexity | uae-f06 | **label** | "…UAE clinic sources cite around 10–15% average loss in trials.[6] \| Typically lower;…" 10% → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; "…UAE clinic sources cite around 10–15% average loss in trials.[6] \| Typically lower;…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C05` | 2026-08-30 | 4 | Gemini | uae-q04 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C05` | 2026-08-30 | 4 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C05` | 2026-08-30 | 4 | Gemini | uae-q23 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-q20 | **label** | "…ectable GLP-1 therapies remaining more effective—oral Wegovy reduces body weight by up to 16.6% compared to Foundayo's 12.4%…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C05` | 2026-08-30 | 4 | Claude | uae-q25 | **label** | "…and Wegovy, are now available in the UAE, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C05` | 2026-08-30 | 4 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C06` | 2026-09-04 | 4 | Gemini | uae-q28 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C06` | 2026-09-04 | 4 | Gemini | uae-q09 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C06` | 2026-09-04 | 4 | ChatGPT | uae-f01 | **label** | "…Wegovy has been shown to lead to a mean weight loss of approximately 17%, whereas Ozempic, when used off-label for weight…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C06` | 2026-09-04 | 4 | ChatGPT | uae-f04 | **label** | "…ignificant weight loss, with participants achieving an average reduction of approximately 15% of their body weight.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C06` | 2026-09-04 | 4 | ChatGPT | uae-f05 | **label** | "…eight loss with Wegovy, with participants achieving an average reduction of approximately 14.9% of their body weight over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C06` | 2026-09-04 | 4 | ChatGPT | uae-q29 | **label** | "…t is administered as a weekly injection and has been shown to reduce body weight by up to 16.6% in clinical trials.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C06` | 2026-09-04 | 4 | ChatGPT | uae-f02 | **label** | "…trials have demonstrated that Wegovy can lead to an average weight loss of approximately 15% of body weight over a 68-week period.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C06` | 2026-09-04 | 4 | ChatGPT | uae-q31 | **label** | "…Studies indicate an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C06` | 2026-09-04 | 4 | ChatGPT | uae-q04 | **label** | "…ical trials have demonstrated significant weight loss, with some patients achieving up to 16.6% reduction.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-f04 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 percent…" 16.6% → label [E-OASIS4-tp]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-f01 | **label** | "…In clinical trials, the Wegovy pill led to an average weight loss of around 16.6 per cent in 64 weeks, when patients took the highest 25mg…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-f05 | **label** | "…The highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct]; "…Clinical data suggests Rybelsus produces 5-10% of body weight loss compared to Wegovy's 15-17%…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Clinical data suggests Rybelsus produces 5-10% of body weight loss compared to Wegovy's 15-17%…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-q31 | **label** | "…Clinical trials show that Wegovy can help patients lose an average of 15% of their body weight over 68 weeks when paired wi…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-f03 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct]; "…egovy pill is your best option since it's newly approved, offers strong clinical results (13.6% weight loss at highest dose), requires no special…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-q30 | **label** | "…and Wegovy, are now available in the UAE, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-q29 | **label** | "…In a 68-week study, people taking Wegovy lost nearly 16% of their starting weight, on average, compared wi…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-q27 | **label** | "…t alternative to Zepbound is Wegovy (semaglutide), another injectable GLP-1 that produces 15% average body weight loss.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-f06 | **label** | "…ctable GLP-1 therapies remaining more effective—oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-q04 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-f02 | **no-source** | "…of 20.2% of their body weight while those taking semaglutide (Wegovy) lost an average of 13.7% over the same period.…" 13.7% → label [E-STEP9-pct]; "…At 12 months, adults on tirzepatide lost about 15% of their body weight compared with 8.3% for semaglutide.…" 8.3% → no-source; "…13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C06` | 2026-09-04 | 4 | Gemini | uae-f01 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C06` | 2026-09-04 | 4 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C06` | 2026-09-04 | 4 | Gemini | uae-f02 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C06` | 2026-09-04 | 4 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C06` | 2026-09-04 | 4 | Perplexity | uae-f06 | **label** | "…ported to produce more weight loss than Saxenda, with UAE clinic materials citing roughly 15–17% average loss for Wegovy versus about 5–8% for Sax…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…ported to produce more weight loss than Saxenda, with UAE clinic materials citing roughly 15–17% average loss for Wegovy versus about 5–8% for Sax…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C06` | 2026-09-04 | 4 | Perplexity | uae-f03 | **label** | "…sed comparison reports about 20–21% average weight reduction for tirzepatide versus about 15% for Wegovy (semaglutide 2.4 mg).[1] That means th…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…\| Weight-loss effectiveness \| Very effective; around 15% average reduction in comparative data[1] \| Usuall…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C06` | 2026-09-04 | 4 | Gemini | uae-q29 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C06` | 2026-09-04 | 4 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C06` | 2026-09-04 | 4 | Gemini | uae-q31 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C06` | 2026-09-04 | 4 | Perplexity | uae-q27 | **label** | "…me GLP-1 alternative for weight management, with reported average weight reduction around 15%.[1][7]…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C06` | 2026-09-04 | 4 | Perplexity | uae-q04 | **label** | "…comparison table lists approximate average weight reduction as Mounjaro ~20–21%, Wegovy ~15%, oral semaglutide ~17%, and Qsymia ~9.8%.[1]…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…approximate average weight reduction as Mounjaro ~20–21%, Wegovy ~15%, oral semaglutide ~17%, and Qsymia ~9.8%.[1]…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C06` | 2026-09-04 | 4 | Gemini | uae-q04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-q25 | **label** | "…oundayo reduce body weight by up to 12.4%, while oral Wegovy reduces body weight by up to 16.6%…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-q13 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C06` | 2026-09-04 | 4 | Claude | uae-q06 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C06` | 2026-09-04 | 4 | Perplexity | uae-q32 | **label** | "…- Expected result: Even a modest 5–10% weight loss can improve ovulation, menstrual regu…" 10% → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct] |
| `UAE-C06` | 2026-09-04 | 4 | Perplexity | uae-q20 | **label** | "…that tirzepatide produced up to 22.5% average body-weight loss at 72 weeks, compared with 15% for semaglutide.[20] That makes GLP-1 therapy the…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C07` | 2026-09-09 | 4 | Claude | uae-q18 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C07` | 2026-09-09 | 4 | ChatGPT | uae-f05 | **label** | "…ignificant weight loss, with participants achieving an average reduction of approximately 14.9% of their body weight over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C07` | 2026-09-09 | 4 | ChatGPT | uae-f02 | **label** | "…In the STEP trials, participants experienced an average weight loss of about 15% over 68–72 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C07` | 2026-09-09 | 4 | ChatGPT | uae-q04 | **label** | "…al trials have shown significant weight loss results, with an average reduction of around 15% over 68 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C07` | 2026-09-09 | 4 | ChatGPT | uae-q29 | **label** | "…Studies indicate an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C07` | 2026-09-09 | 4 | ChatGPT | uae-q23 | **label** | "…Clinical trials have demonstrated an average weight loss of 15% over 68 weeks with Wegovy.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C07` | 2026-09-09 | 4 | ChatGPT | uae-q31 | **label** | "…- Efficacy: Clinical trials have demonstrated an average weight loss of approximately 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C07` | 2026-09-09 | 4 | ChatGPT | uae-f06 | **label** | "…cal studies have demonstrated that Wegovy can lead to a mean weight loss of approximately 17% in adults with obesity or overweight conditions.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C07` | 2026-09-09 | 4 | ChatGPT | uae-f04 | **label** | "…ed its effectiveness, with participants achieving an average weight loss of approximately 17%.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C07` | 2026-09-09 | 4 | ChatGPT | uae-f03 | **label** | "…- Wegovy: Clinical studies have demonstrated a mean weight loss of approximately 17% in adults with obesity or overweight conditions.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C07` | 2026-09-09 | 4 | Claude | uae-f01 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C07` | 2026-09-09 | 4 | Claude | uae-f04 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C07` | 2026-09-09 | 4 | Claude | uae-f06 | **label** | "…In head-to-head trials (STEP 8), participants taking Wegovy lost an average of 15.8% of body weight over 68 weeks, compared to 6.4% wi…" 15.8% → label [E-STEP8-pct] |
| `UAE-C07` | 2026-09-09 | 4 | Claude | uae-q31 | **label** | "…P-1 therapies remain more effective, with injectable Wegovy reducing body weight by up to 16.6 per cent…" 16.6% → label [E-OASIS4-tp]; "…Oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C07` | 2026-09-09 | 4 | Claude | uae-f02 | **no-source** | "…% weight loss over six months at the top dose, while Wegovy (semaglutide) achieves around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…% weight loss over six months at the top dose, while Wegovy (semaglutide) achieves around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C07` | 2026-09-09 | 4 | Claude | uae-q27 | **no-source** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp]; "…Around 12 to 15% weight loss over 12 months when paired with lifes…" 12% → no-source; "…Around 12 to 15% weight loss over 12 months when paired with lifes…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C07` | 2026-09-09 | 4 | Claude | uae-f03 | **label** | "…The highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct]; "…govy if: You prefer oral convenience, don't want injections, and are satisfied with solid 13-16% weight loss results…" 13% → label [L-STEP6-2.4-pct, L-STEPUPT2D-7.2-pct]; "…govy if: You prefer oral convenience, don't want injections, and are satisfied with solid 13-16% weight loss results…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C07` | 2026-09-09 | 4 | Gemini | uae-f01 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C07` | 2026-09-09 | 4 | Gemini | uae-f04 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C07` | 2026-09-09 | 4 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp] |
| `UAE-C07` | 2026-09-09 | 4 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct] |
| `UAE-C07` | 2026-09-09 | 4 | Perplexity | uae-f03 | **label** | "…ght loss than Wegovy/semaglutide in the head-to-head trial cited in the sources: 20.2% vs 13.7% over 72 weeks.[19]…" 13.7% → label [E-STEP9-pct] |
| `UAE-C07` | 2026-09-09 | 4 | Perplexity | uae-f02 | **label** | "…loss \| Higher on average; around 20% in some trial comparisons \| Lower on average; around 14–15% in major comparisons[17][1][9] \|…" 14% → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; "…loss \| Higher on average; around 20% in some trial comparisons \| Lower on average; around 14–15% in major comparisons[17][1][9] \|…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C07` | 2026-09-09 | 4 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP8-pct] |
| `UAE-C07` | 2026-09-09 | 4 | Perplexity | uae-f06 | **label** | "…\| Effectiveness \| Typically around 15–17% average weight loss in clinic/trial summaries cit…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…\| Effectiveness \| Typically around 15–17% average weight loss in clinic/trial summaries cit…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C07` | 2026-09-09 | 4 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C07` | 2026-09-09 | 4 | ChatGPT | uae-q06 | **label** | "…al trials have shown that semaglutide can lead to an average weight loss of approximately 15% over about 68 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C07` | 2026-09-09 | 4 | Gemini | uae-q01 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C07` | 2026-09-09 | 4 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C07` | 2026-09-09 | 4 | Perplexity | uae-q13 | **label** | "…tide 2.4 mg \| Registered in the UAE for weight management and commonly prescribed \| About 15–17% average weight loss in trials[9][11] \|…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…tide 2.4 mg \| Registered in the UAE for weight management and commonly prescribed \| About 15–17% average weight loss in trials[9][11] \|…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C07` | 2026-09-09 | 4 | Perplexity | uae-q25 | **label** | "…- First 1–3 months: fewer cravings, improved appetite control, and around 3–8% loss for many structured programs.[2][4][7][13][1…" 8% → label [L-STEP4-pct]; "…- Around 6 months: roughly 5–15% loss is plausible depending on treatment intensit…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C08` | 2026-09-11 | 4 | Claude | uae-q18 | **label** | "…ide the United States to make the Wegovy® pill available, providing a mean weight loss of 17% and being the only weight-loss pill approved to r…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C08` | 2026-09-11 | 4 | Claude | uae-q21 | **label** | "…Wegovy reduces body weight by up to 16.6% compared to Foundayo's 12.4%.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C08` | 2026-09-11 | 4 | ChatGPT | uae-f04 | **label** | "…icant weight loss, with some participants achieving an average reduction of approximately 15% of their body weight over a 14-month period.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C08` | 2026-09-11 | 4 | ChatGPT | uae-f05 | **label** | "…ignificant weight loss, with participants achieving an average reduction of approximately 14.9% of their body weight over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C08` | 2026-09-11 | 4 | ChatGPT | uae-q04 | **label** | "…Clinical trials have shown an average weight loss of approximately 15% over 68 weeks when combined with a reduced-calori…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C08` | 2026-09-11 | 4 | ChatGPT | uae-q31 | **label** | "…Clinical trials indicate an average weight loss of around 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C08` | 2026-09-11 | 4 | ChatGPT | uae-f02 | **label** | "…In the STEP UP trial, adults with obesity lost an average of 21% of their body weight over 72 weeks when taking se…" 21% → label [E-STEPUP-7.2-tp] |
| `UAE-C08` | 2026-09-11 | 4 | ChatGPT | uae-q29 | **label** | "…nical trials have demonstrated significant weight loss, with some studies reporting up to 16.6% reduction in body weight.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C08` | 2026-09-11 | 4 | ChatGPT | uae-f03 | **label** | "…- Wegovy: Clinical studies have demonstrated a mean weight loss of approximately 17% of initial body weight.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C08` | 2026-09-11 | 4 | Claude | uae-f04 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C08` | 2026-09-11 | 4 | Claude | uae-f01 | **label** | "…In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated ~17% mean weight loss, and is similar to that of injec…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C08` | 2026-09-11 | 4 | Claude | uae-f05 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C08` | 2026-09-11 | 4 | Claude | uae-f02 | **label** | "…with people losing an average of 20.2% of their body weight with tirzepatide compared to 13.7% with semaglutide.…" 13.7% → label [E-STEP9-pct]; "…Wegovy patients taking the highest oral dose experienced an average weight loss of around 16.6% over 64 weeks when combined with lifestyle change…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C08` | 2026-09-11 | 4 | Claude | uae-q27 | **no-source** | "…It produces approximately 12 to 15% weight loss over 12 months when paired with lifes…" 12% → no-source; "…It produces approximately 12 to 15% weight loss over 12 months when paired with lifes…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C08` | 2026-09-11 | 4 | Claude | uae-q04 | **no-source** | "…Studies suggest an average weight loss of 15-20%…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Studies suggest an average weight loss of 15-20%…" 20% → no-source; "…\| Average Weight Loss \| 15-20% \| Not yet published…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…\| Average Weight Loss \| 15-20% \| Not yet published…" 20% → no-source |
| `UAE-C08` | 2026-09-11 | 4 | Claude | uae-q29 | **label** | "…ht with Wegovy compared with Saxenda—in a 68-week study, people taking Wegovy lost nearly 16% of their starting weight on average, compared wit…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C08` | 2026-09-11 | 4 | Claude | uae-f06 | **label** | "…8 trial), patients on 3mg Saxenda daily lost 6.4% body weight over 68 weeks, compared to 15.8% with Wegovy…" 15.8% → label [E-STEP8-pct]; "…Oral Wegovy reduces body weight by up to 16.6%, compared to Foundayo's 12.4%…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C08` | 2026-09-11 | 4 | Gemini | uae-f04 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C08` | 2026-09-11 | 4 | Gemini | uae-q31 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C08` | 2026-09-11 | 4 | Gemini | uae-f02 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C08` | 2026-09-11 | 4 | Gemini | uae-f01 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C08` | 2026-09-11 | 4 | Gemini | uae-f06 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP3-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C08` | 2026-09-11 | 4 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct] |
| `UAE-C08` | 2026-09-11 | 4 | Gemini | uae-f03 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct] |
| `UAE-C08` | 2026-09-11 | 4 | Perplexity | uae-f04 | **label** | "…or effectiveness: oral Wegovy (semaglutide 25 mg) has reported average weight loss around 13.6% to 17% in trials, with about 1 in 3 people losing 20% or…" 13.6% → label [L-OASIS4-pct]; "…or effectiveness: oral Wegovy (semaglutide 25 mg) has reported average weight loss around 13.6% to 17% in trials, with about 1 in 3 people losing 20% or…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C08` | 2026-09-11 | 4 | Gemini | uae-q04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C08` | 2026-09-11 | 4 | Gemini | uae-q23 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C08` | 2026-09-11 | 4 | Perplexity | uae-f06 | **label** | "…\| Typical weight-loss effect \| About 15–17% in UAE clinic guidance and related local market r…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…\| Typical weight-loss effect \| About 15–17% in UAE clinic guidance and related local market r…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C08` | 2026-09-11 | 4 | Perplexity | uae-f03 | **label** | "…-head trial cited by Maven Clinic reported 20.2% average weight loss with Zepbound versus 13.7% with Wegovy over 72 weeks.[18] But if you mean wh…" 13.7% → label [E-STEP9-pct] |
| `UAE-C08` | 2026-09-11 | 4 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C08` | 2026-09-11 | 4 | Claude | uae-q06 | **no-source** | "…Clinical studies indicate patients may achieve an average body weight reduction of around 12 per cent over time.…" 12% → no-source |
| `UAE-C08` | 2026-09-11 | 4 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C08` | 2026-09-11 | 4 | Perplexity | uae-q25 | **label** | "…UAE clinics and can reach much higher trial-based results, with quoted averages of about 15% body-weight loss for semaglutide and up to 21–22.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C09` | 2026-09-14 | 4 | Gemini | uae-q26 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C09` | 2026-09-14 | 4 | Claude | uae-q18 | **label** | "…Wegovy pill provides a mean weight loss of 17% and is the only weight-loss pill approved to redu…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C09` | 2026-09-14 | 4 | ChatGPT | uae-f04 | **label** | "…d that Wegovy can lead to significant weight loss, with participants losing an average of 15% of their body weight over a period of 14 months.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C09` | 2026-09-14 | 4 | ChatGPT | uae-q31 | **label** | "…ess: Clinical studies have demonstrated significant weight loss, with reductions of up to 16.6% of body weight.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C09` | 2026-09-14 | 4 | ChatGPT | uae-f05 | **label** | "…pproved for chronic weight management, leading to an average weight loss of approximately 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C09` | 2026-09-14 | 4 | Claude | uae-f04 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct]; "…oral Wegovy generally produces slightly higher average weight loss between 13.6 and 16.6 per cent body-weight reduction than Foundayo (between 11-1…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C09` | 2026-09-14 | 4 | Claude | uae-q31 | **label** | "…jectable GLP-1 therapies remain more effective, with Wegovy reducing body weight by up to 16.6 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C09` | 2026-09-14 | 4 | Claude | uae-f06 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp]; "…xenda) showed about 6% weight loss over 68 weeks, while semaglutide (Wegovy) led to about 16% weight loss.…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C09` | 2026-09-14 | 4 | Claude | uae-f02 | **no-source** | "…jaro sits at around 20% weight loss over six months at the top dose, and Wegovy at around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…jaro sits at around 20% weight loss over six months at the top dose, and Wegovy at around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C09` | 2026-09-14 | 4 | Claude | uae-q27 | **no-source** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp]; "…cipants who took orforglipron lost more weight – an average of 6.1kg-8.2kg, compared with 5.3kg in those taking semaglutide.…" 5.3kg → no-source |
| `UAE-C09` | 2026-09-14 | 4 | Claude | uae-q04 | **no-source** | "…semaglutide delivers average body weight reduction of 12–15%…" 12% → no-source; "…semaglutide delivers average body weight reduction of 12–15%…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C09` | 2026-09-14 | 4 | Claude | uae-f03 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C09` | 2026-09-14 | 4 | Claude | uae-q29 | **label** | "…In a 68-week study, people taking Wegovy lost nearly 16% of their starting weight, on average, compared wi…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C09` | 2026-09-14 | 4 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp] |
| `UAE-C09` | 2026-09-14 | 4 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C09` | 2026-09-14 | 4 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C09` | 2026-09-14 | 4 | Gemini | uae-f04 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C09` | 2026-09-14 | 4 | Perplexity | uae-f03 | **label** | "…er average weight loss than semaglutide (Wegovy) in the main head-to-head trial: 20.2% vs 13.7% over 72 weeks.[20] That makes Zepbound/tirzepatid…" 13.7% → label [E-STEP9-pct] |
| `UAE-C09` | 2026-09-14 | 4 | Perplexity | uae-f04 | **label** | "…effective, but not a shortcut: clinical trial results cited in UAE coverage show roughly 13.6% to 17% average weight loss with oral Wegovy depending on…" 13.6% → label [L-OASIS4-pct]; "…effective, but not a shortcut: clinical trial results cited in UAE coverage show roughly 13.6% to 17% average weight loss with oral Wegovy depending on…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…- Meaningful results: UAE sources describe weight loss broadly in the 10%–17% range, which is clinically significant for obesit…" 10% → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; "…- Meaningful results: UAE sources describe weight loss broadly in the 10%–17% range, which is clinically significant for obesit…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C09` | 2026-09-14 | 4 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C09` | 2026-09-14 | 4 | Gemini | uae-q29 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C09` | 2026-09-14 | 4 | Gemini | uae-q04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C09` | 2026-09-14 | 4 | Perplexity | uae-q27 | **label** | "…alternative specifically for chronic weight management; one UAE source lists it at about 15% average weight reduction.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Useful if you want a tablet rather than an injection; one UAE comparison places it around 17% average weight reduction.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C09` | 2026-09-14 | 4 | ChatGPT | uae-q06 | **label** | "…For instance, the OASIS-4 trial reported an average weight loss of 17% over 68 weeks with semaglutide treatment.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C09` | 2026-09-14 | 4 | Claude | uae-q20 | **label** | "…Wegovy showed greater weight loss in clinical trials, with an average 14% body weight reduction…" 14% → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; "…it showed an average 11% body weight reduction compared with 14% for Wegovy…" 14% → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C09` | 2026-09-14 | 4 | Perplexity | uae-q25 | **label** | "…Wegovy/Ozempic/Mounjaro: UAE providers market these around trial-based results of roughly 15% weight loss with semaglutide and up to 22.5% with…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C10` | 2026-09-16 | 4 | ChatGPT | uae-f04 | **label** | "…ed its effectiveness, with participants achieving an average weight loss of approximately 15% over 14 months.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C10` | 2026-09-16 | 4 | ChatGPT | uae-q23 | **label** | "…cal trials have shown significant weight loss results, with some patients achieving up to 15% weight reduction.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C10` | 2026-09-16 | 4 | ChatGPT | uae-f05 | **label** | "…For instance, the STEP-1 trial showed a mean weight loss of 14.9% over 68 weeks with Wegovy.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C10` | 2026-09-16 | 4 | ChatGPT | uae-f02 | **label** | "…In the STEP trials, participants experienced an average weight loss of about 15% over 68–72 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C10` | 2026-09-16 | 4 | Claude | uae-f01 | **label** | "…In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated ~17% mean weight loss, and the weight loss achieved wi…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C10` | 2026-09-16 | 4 | Claude | uae-f05 | **label** | "…The highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct]; "…oral Wegovy reduces body weight by up to 16.6 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C10` | 2026-09-16 | 4 | Claude | uae-q30 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C10` | 2026-09-16 | 4 | Claude | uae-q04 | **label** | "…ective FDA-approved medication for weight loss with clinical trials showing an average of 10% body weight reduction over 68 weeks…" 10% → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct] |
| `UAE-C10` | 2026-09-16 | 4 | Claude | uae-q29 | **label** | "…with Wegovy compared with Saxenda, with studies showing people taking Wegovy lost nearly 16% of their starting weight, on average, compared wi…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C10` | 2026-09-16 | 4 | Claude | uae-f03 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C10` | 2026-09-16 | 4 | Claude | uae-q23 | **label** | "…Wegovy (semaglutide 2.4 mg, weekly) typically produces 15–17% weight loss.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Wegovy (semaglutide 2.4 mg, weekly) typically produces 15–17% weight loss.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C10` | 2026-09-16 | 4 | Claude | uae-q27 | **label** | "…Oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C10` | 2026-09-16 | 4 | Claude | uae-f06 | **label** | "…xenda) showed about 6% weight loss over 68 weeks, while semaglutide (Wegovy) led to about 16% weight loss.…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; "…linical trial (OASIS 4) showed that the once-daily 25 mg Wegovy pill delivered an average 17% weight loss, comparable to the injectable version…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C10` | 2026-09-16 | 4 | Claude | uae-f02 | **no-source** | "…sitting at around 20% over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…sitting at around 20% over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…o has helped people lose up to 22.5% of their starting weight, the Wegovy injection up to 21%…" 21% → label [E-STEPUP-7.2-tp] |
| `UAE-C10` | 2026-09-16 | 4 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C10` | 2026-09-16 | 4 | Gemini | uae-f05 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C10` | 2026-09-16 | 4 | Gemini | uae-f01 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C10` | 2026-09-16 | 4 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp] |
| `UAE-C10` | 2026-09-16 | 4 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp] |
| `UAE-C10` | 2026-09-16 | 4 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C10` | 2026-09-16 | 4 | Gemini | uae-q04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C10` | 2026-09-16 | 4 | Perplexity | uae-f06 | **label** | "…\| Typical weight-loss signal \| About 15–17% in UAE clinic materials; broader medical sources…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…\| Typical weight-loss signal \| About 15–17% in UAE clinic materials; broader medical sources…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…l weight-loss signal \| About 15–17% in UAE clinic materials; broader medical sources cite 10–15%+ in trials \| About 5–8% in UAE clinic materials;…" 10% → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; "…l weight-loss signal \| About 15–17% in UAE clinic materials; broader medical sources cite 10–15%+ in trials \| About 5–8% in UAE clinic materials;…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C10` | 2026-09-16 | 4 | Perplexity | uae-f03 | **label** | "…idely cited trial comparison reported 20.2% body-weight loss with Zepbound/tirzepatide vs 13.7% with Wegovy/semaglutide over 72 weeks.[14] Source…" 13.7% → label [E-STEP9-pct] |
| `UAE-C10` | 2026-09-16 | 4 | Gemini | uae-q29 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C10` | 2026-09-16 | 4 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C10` | 2026-09-16 | 4 | Perplexity | uae-q04 | **label** | "…t mainstream alternative for dedicated weight management, with average weight loss around 15% in comparative UAE material and broad UAE pharmac…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C10` | 2026-09-16 | 4 | ChatGPT | uae-q06 | **label** | "…l studies have shown that semaglutide can lead to an average weight loss of approximately 17% over 68 weeks.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C10` | 2026-09-16 | 4 | Claude | uae-q20 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C11` | 2026-09-21 | 4 | Claude | uae-q22 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C11` | 2026-09-21 | 4 | ChatGPT | uae-q23 | **label** | "…Studies indicate an average weight loss of approximately 15% over 68 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C11` | 2026-09-21 | 4 | ChatGPT | uae-f02 | **label** | "…For instance, in the STEP trials, participants lost an average of about 15% of their body weight over 68–72 weeks when taking…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C11` | 2026-09-21 | 4 | ChatGPT | uae-f05 | **label** | "…In the STEP-1 trial, participants using Wegovy experienced an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C11` | 2026-09-21 | 4 | ChatGPT | uae-f03 | **label** | "…Wegovy has shown a mean weight loss of 17%, while tirzepatide (Mounjaro/Zepbound) has demons…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C11` | 2026-09-21 | 4 | ChatGPT | uae-q29 | **label** | "…It has demonstrated effectiveness in weight reduction, with patients experiencing up to 16.6% body weight loss in clinical studies.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C11` | 2026-09-21 | 4 | ChatGPT | uae-q04 | **label** | "…Clinical studies have demonstrated an average weight loss of around 15% over 68 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C11` | 2026-09-21 | 4 | Claude | uae-f04 | **no-source** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp]; "…s at around 20% weight loss over six months at the top dose, while Wegovy achieves around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…s at around 20% weight loss over six months at the top dose, while Wegovy achieves around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C11` | 2026-09-21 | 4 | Claude | uae-f05 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C11` | 2026-09-21 | 4 | Claude | uae-f06 | **label** | "…injectable GLP-1 therapies show oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C11` | 2026-09-21 | 4 | Claude | uae-f03 | **label** | "…duces greater average weight loss than Wegovy at 72 weeks in adults with obesity—20.2% vs 13.7%…" 13.7% → label [E-STEP9-pct]; "…The highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C11` | 2026-09-21 | 4 | Claude | uae-q23 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent, and oral pi…" 16.6% → label [E-OASIS4-tp]; "…ed in June by Novo Nordisk as a Wegovy pill, and oral Wegovy reduces body weight by up to 16.6 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C11` | 2026-09-21 | 4 | Claude | uae-q31 | **no-source** | "…jaro sits at around 20% weight loss over six months at the top dose, and Wegovy at around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…jaro sits at around 20% weight loss over six months at the top dose, and Wegovy at around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C11` | 2026-09-21 | 4 | Claude | uae-q29 | **no-source** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks.…" 13.6% → label [L-OASIS4-pct]; "…eight loss, with Mounjaro at around 20% over six months at top dose, and Wegovy at around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…eight loss, with Mounjaro at around 20% over six months at top dose, and Wegovy at around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C11` | 2026-09-21 | 4 | Claude | uae-f02 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C11` | 2026-09-21 | 4 | Gemini | uae-f01 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C11` | 2026-09-21 | 4 | Claude | uae-q27 | **label** | "…Foundayo's oral form reduces body weight by 12.4% compared to injectable Wegovy's 16.6%.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C11` | 2026-09-21 | 4 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C11` | 2026-09-21 | 4 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C11` | 2026-09-21 | 4 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C11` | 2026-09-21 | 4 | Gemini | uae-q04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct] |
| `UAE-C11` | 2026-09-21 | 4 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C11` | 2026-09-21 | 4 | Gemini | uae-q31 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C11` | 2026-09-21 | 4 | Gemini | uae-f03 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp] |
| `UAE-C11` | 2026-09-21 | 4 | Claude | uae-q13 | **label** | "…ost effective weight loss medication available in Dubai, producing average weight loss of 15% of body weight in clinical trials.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C11` | 2026-09-21 | 4 | Gemini | uae-q13 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C11` | 2026-09-21 | 4 | Gemini | uae-q25 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP3-kg, E-STEPUP-2.4-kg] |
| `UAE-C11` | 2026-09-21 | 4 | Perplexity | uae-q25 | **label** | "…- Medium term: about 5–10% loss is a common practical outcome for structured…" 10% → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; "…ium term: about 5–10% loss is a common practical outcome for structured programmes, while 10%+ is more likely with prescription medicines and c…" 10% → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct] |
| `UAE-C12` | 2026-09-23 | 4 | Claude | uae-q18 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C12` | 2026-09-23 | 4 | ChatGPT | uae-f04 | **label** | "…ignificant weight loss, with participants achieving an average reduction of approximately 15% of their body weight over a 14-month period.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C12` | 2026-09-23 | 4 | ChatGPT | uae-q29 | **label** | "…Clinical studies indicate an average weight loss of approximately 15% of body weight.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C12` | 2026-09-23 | 4 | ChatGPT | uae-f05 | **label** | "…For instance, the STEP-1 trial reported a mean weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C12` | 2026-09-23 | 4 | Claude | uae-f05 | **label** | "…In the OASIS 4 trial, adults who took the 25 mg Wegovy tablet lost an average of 13.6% of body weight over 64 weeks.…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C12` | 2026-09-23 | 4 | Claude | uae-f01 | **no-source** | "…Wegovy (semaglutide) delivers around 12 to 15% weight loss over 12 months when paired with lifes…" 12% → no-source; "…Wegovy (semaglutide) delivers around 12 to 15% weight loss over 12 months when paired with lifes…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C12` | 2026-09-23 | 4 | Claude | uae-f02 | **label** | "…f 22.5% of their starting body weight, while those taking Wegovy 7.2mg lost an average of 21%.…" 21% → label [E-STEPUP-7.2-tp] |
| `UAE-C12` | 2026-09-23 | 4 | Claude | uae-q31 | **label** | "…tends to produce greater weight loss than other alternatives, with patients losing about 15% of their body weight over 68 weeks…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Saxenda users lost closer to 8% of body weight compared to Wegovy's 15%…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C12` | 2026-09-23 | 4 | Claude | uae-f06 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp]; "…linical trial (OASIS 4) showed that the once-daily 25 mg Wegovy pill delivered an average 17% weight loss, comparable to the injectable version…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C12` | 2026-09-23 | 4 | Claude | uae-f04 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C12` | 2026-09-23 | 4 | Claude | uae-q27 | **no-source** | "…Semaglutide's results range from 12-15% weight reduction…" 12% → no-source; "…Semaglutide's results range from 12-15% weight reduction…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C12` | 2026-09-23 | 4 | Claude | uae-f03 | **label** | "…linical trial (OASIS 4) showed that the once-daily 25 mg Wegovy pill delivered an average 17% weight loss, comparable to the injectable version…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C12` | 2026-09-23 | 4 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp] |
| `UAE-C12` | 2026-09-23 | 4 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C12` | 2026-09-23 | 4 | Gemini | uae-f01 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C12` | 2026-09-23 | 4 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct] |
| `UAE-C12` | 2026-09-23 | 4 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP8-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C12` | 2026-09-23 | 4 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct] |
| `UAE-C12` | 2026-09-23 | 4 | Perplexity | uae-f04 | **label** | "…strong efficacy: UAE reports and trial data cited locally put average weight loss around 16.6% over about a year in people who stayed on treatme…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C12` | 2026-09-23 | 4 | Perplexity | uae-f06 | **label** | "…\| Weight-loss effectiveness \| Typically reported around 15–17% average weight loss \| Typically reported around 5…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…\| Weight-loss effectiveness \| Typically reported around 15–17% average weight loss \| Typically reported around 5…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C12` | 2026-09-23 | 4 | Gemini | uae-q23 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C12` | 2026-09-23 | 4 | Gemini | uae-q04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C12` | 2026-09-23 | 4 | Gemini | uae-q31 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C12` | 2026-09-23 | 4 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C12` | 2026-09-23 | 4 | Gemini | uae-q01 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source |
| `UAE-C12` | 2026-09-23 | 4 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C12` | 2026-09-23 | 4 | Perplexity | uae-q25 | **label** | "…ed result is usually larger: UAE clinic materials and trial summaries commonly cite about 15–17% average loss for semaglutide (Wegovy) and 18–22%…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…ed result is usually larger: UAE clinic materials and trial summaries commonly cite about 15–17% average loss for semaglutide (Wegovy) and 18–22%…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…- Wegovy-class treatment: often around 15–17% average loss in trials and clinic guidance.[5][11…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…- Wegovy-class treatment: often around 15–17% average loss in trials and clinic guidance.[5][11…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C13` | 2026-09-25 | 4 | Claude | uae-q19 | **label** | "…Semaglutide (branded as Ozempic for diabetes, Wegovy for weight loss) produces an average 14.9% body weight loss over 68 weeks in the STEP 1 tria…" 14.9% → label [L-STEP1-pct] |
| `UAE-C13` | 2026-09-25 | 4 | ChatGPT | uae-q14 | **label** | "…l medication approved for weight management, offering a mean weight loss of approximately 17%.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C13` | 2026-09-25 | 4 | ChatGPT | uae-f04 | **label** | "…studies have demonstrated that Wegovy can lead to an average weight loss of approximately 15% over a period of 14 months.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C13` | 2026-09-25 | 4 | ChatGPT | uae-f03 | **label** | "…n that Wegovy can lead to significant weight loss, with a mean reduction of approximately 17% of body weight.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C13` | 2026-09-25 | 4 | ChatGPT | uae-f02 | **label** | "…f 20.2% of their body weight over 72 weeks, while those on semaglutide lost an average of 13.7% over the same period.…" 13.7% → label [E-STEP9-pct] |
| `UAE-C13` | 2026-09-25 | 4 | ChatGPT | uae-f05 | **label** | "…In the STEP-1 trial, participants using Wegovy experienced an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C13` | 2026-09-25 | 4 | ChatGPT | uae-q31 | **label** | "…stered as a weekly injection and has demonstrated an average weight loss of approximately 15% of body weight in clinical studies.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C13` | 2026-09-25 | 4 | ChatGPT | uae-q29 | **label** | "…Clinical trials have demonstrated an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C13` | 2026-09-25 | 4 | Claude | uae-f01 | **label** | "…Clinical trials show Wegovy® patients achieve approximately 15-18% weight loss over 68 weeks, while Ozempic® results…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Clinical trials show Wegovy® patients achieve approximately 15-18% weight loss over 68 weeks, while Ozempic® results…" 18% → label [E-STEP3-tp, E-STEPUP-2.4-tp, E-TEENS-bmi-tp] |
| `UAE-C13` | 2026-09-25 | 4 | Claude | uae-f04 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6% compared to Foundayo's 12.4%…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C13` | 2026-09-25 | 4 | Claude | uae-f02 | **no-source** | "…round 20% weight loss over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…round 20% weight loss over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C13` | 2026-09-25 | 4 | Claude | uae-q27 | **no-source** | "…Studies suggest an average weight loss of 15-20%.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Studies suggest an average weight loss of 15-20%.…" 20% → no-source |
| `UAE-C13` | 2026-09-25 | 4 | Claude | uae-f06 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp]; "…The highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C13` | 2026-09-25 | 4 | Claude | uae-q29 | **no-source** | "…Wegovy achieves around 12 to 15% weight loss over 12 months when paired with lifes…" 12% → no-source; "…Wegovy achieves around 12 to 15% weight loss over 12 months when paired with lifes…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C13` | 2026-09-25 | 4 | Gemini | uae-f01 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C13` | 2026-09-25 | 4 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C13` | 2026-09-25 | 4 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct] |
| `UAE-C13` | 2026-09-25 | 4 | Perplexity | uae-f04 | **label** | "…ded options available locally: UAE reporting on the oral version says trials showed about 16.6%–17% average weight loss over roughly a year when take…" 16.6% → label [E-OASIS4-tp]; "…ded options available locally: UAE reporting on the oral version says trials showed about 16.6%–17% average weight loss over roughly a year when take…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C13` | 2026-09-25 | 4 | Perplexity | uae-f02 | **label** | "…UAE reporting on the pill notes about 13.6%–16.6% average body-weight reduction in clinical tests.[…" 13.6% → label [L-OASIS4-pct]; "…UAE reporting on the pill notes about 13.6%–16.6% average body-weight reduction in clinical tests.[…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C13` | 2026-09-25 | 4 | Perplexity | uae-f06 | **label** | "…\| Weight-loss effectiveness \| Higher; commonly cited around 15–17% in UAE clinic materials \| Lower; commonly cited a…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…\| Weight-loss effectiveness \| Higher; commonly cited around 15–17% in UAE clinic materials \| Lower; commonly cited a…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C13` | 2026-09-25 | 4 | Gemini | uae-q29 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C13` | 2026-09-25 | 4 | Perplexity | uae-q04 | **label** | "…loss clinics[1][2][12] \| Strong, usually the closest mainstream alternative; cited around 15–17% vs Mounjaro’s 18–22%[2][9] \|…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…loss clinics[1][2][12] \| Strong, usually the closest mainstream alternative; cited around 15–17% vs Mounjaro’s 18–22%[2][9] \|…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C13` | 2026-09-25 | 4 | Perplexity | uae-q27 | **label** | "…son puts average weight-loss signals at about 20–21% for tirzepatide (Mounjaro) and about 15% for Wegovy, which is why Mounjaro is usually the…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C13` | 2026-09-25 | 4 | Perplexity | uae-q29 | **label** | "…raglutide injection with about 5–8% average weight loss, while Wegovy is described around 15–17% and Mounjaro around 18–22%.[2][6]…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…raglutide injection with about 5–8% average weight loss, while Wegovy is described around 15–17% and Mounjaro around 18–22%.[2][6]…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C13` | 2026-09-25 | 4 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C13` | 2026-09-25 | 4 | Claude | uae-q10 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C13` | 2026-09-25 | 4 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP5-kg]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct] |
| `UAE-C14` | 2026-09-27 | 5 | Gemini | uae-q17 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C14` | 2026-09-27 | 5 | ChatGPT | uae-f04 | **label** | "…ignificant weight loss, with participants achieving an average reduction of approximately 15% of their body weight over a 14-month period.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C14` | 2026-09-27 | 5 | ChatGPT | uae-f03 | **label** | "…y: Clinical trials have shown that Wegovy can lead to a mean weight loss of approximately 17% of initial body weight.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C14` | 2026-09-27 | 5 | ChatGPT | uae-q04 | **label** | "…It has demonstrated an average weight loss of about 15% over 68 weeks in clinical studies.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C14` | 2026-09-27 | 5 | ChatGPT | uae-f05 | **label** | "…Clinical trials have demonstrated a mean weight loss of approximately 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C14` | 2026-09-27 | 5 | ChatGPT | uae-q29 | **label** | "…Studies indicate an average weight loss of approximately 15% over 68 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C14` | 2026-09-27 | 5 | ChatGPT | uae-f06 | **label** | "…- Oral Form: Clinical trials indicate a mean weight loss of approximately 17% over 68 weeks.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…- Injectable Form: Similar efficacy, with a mean weight loss of about 13.6% over 64 weeks.…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C14` | 2026-09-27 | 5 | Claude | uae-f04 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C14` | 2026-09-27 | 5 | Claude | uae-f01 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks.…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C14` | 2026-09-27 | 5 | Claude | uae-f05 | **label** | "…y pill is a 25 mg tablet licensed for weight loss, and produced an average weight loss of 13.6% in trials…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C14` | 2026-09-27 | 5 | Claude | uae-q29 | **label** | "…In a 68-week study, people taking Wegovy lost nearly 16% of their starting weight, on average, compared wi…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C14` | 2026-09-27 | 5 | Claude | uae-q04 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C14` | 2026-09-27 | 5 | Claude | uae-q31 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C14` | 2026-09-27 | 5 | Claude | uae-f02 | **no-source** | "…round 20% weight loss over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…round 20% weight loss over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…f 22.5% of their starting body weight, while those taking Wegovy 7.2mg lost an average of 21%…" 21% → label [E-STEPUP-7.2-tp] |
| `UAE-C14` | 2026-09-27 | 5 | Claude | uae-f06 | **label** | "…that patients who took Saxenda lost 6.4% of their body weight over 68 weeks, compared to 15.8% with Wegovy…" 15.8% → label [E-STEP8-pct] |
| `UAE-C14` | 2026-09-27 | 5 | Claude | uae-f03 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C14` | 2026-09-27 | 5 | Gemini | uae-f01 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C14` | 2026-09-27 | 5 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C14` | 2026-09-27 | 5 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C14` | 2026-09-27 | 5 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP3-tp, E-STEPUP-2.4-tp, E-TEENS-bmi-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct] |
| `UAE-C14` | 2026-09-27 | 5 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C14` | 2026-09-27 | 5 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C14` | 2026-09-27 | 5 | Perplexity | uae-f04 | **label** | "…- Effective, but not magic: Trial results cited in UAE coverage put average loss around 15% to 17% over roughly a year with proper use, with some pe…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…- Effective, but not magic: Trial results cited in UAE coverage put average loss around 15% to 17% over roughly a year with proper use, with some pe…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C14` | 2026-09-27 | 5 | Gemini | uae-q29 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C14` | 2026-09-27 | 5 | Perplexity | uae-q27 | **label** | "…g; widely recognized in UAE weight-loss clinics and pharmacies \| Weekly injection \| About 15% \| Best alternative if you want a branded, weight-…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C14` | 2026-09-27 | 5 | Perplexity | uae-q31 | **label** | "…weight management in the UAE and commonly cited as available there[1][5][7][16] \| Around 15–17%[1][5][12] \| Best direct alternative to Ozempic fo…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…weight management in the UAE and commonly cited as available there[1][5][7][16] \| Around 15–17%[1][5][12] \| Best direct alternative to Ozempic fo…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C14` | 2026-09-27 | 5 | Gemini | uae-q04 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C14` | 2026-09-27 | 5 | Gemini | uae-q13 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C14` | 2026-09-27 | 5 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C14` | 2026-09-27 | 5 | Perplexity | uae-q06 | **label** | "…rting also notes that oral semaglutide trials showed average weight reductions of roughly 15% over about 68 weeks, with improvements in metabol…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C15` | 2026-09-29 | 5 | Claude | uae-q18 | **label** | "…In clinical trials, average weight loss was about 17% of total body weight with the Wegovy pill (oral s…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C15` | 2026-09-29 | 5 | Gemini | uae-q28 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C15` | 2026-09-29 | 5 | ChatGPT | uae-f05 | **label** | "…Clinical trials have demonstrated a mean weight loss of approximately 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C15` | 2026-09-29 | 5 | ChatGPT | uae-f01 | **label** | "…Clinical studies have shown that Wegovy leads to a mean weight loss of approximately 17%, with some individuals losing up to 20% of their…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C15` | 2026-09-29 | 5 | ChatGPT | uae-q04 | **label** | "…Clinical studies have demonstrated an average weight loss of about 15% over 68 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C15` | 2026-09-29 | 5 | ChatGPT | uae-f03 | **label** | "…significant weight loss, with some trials reporting an average reduction of approximately 17% of body weight.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C15` | 2026-09-29 | 5 | ChatGPT | uae-f02 | **label** | "…ty lost an average of 20.2% of their body weight over 72 weeks with Mounjaro, compared to 13.7% with Wegovy.…" 13.7% → label [E-STEP9-pct] |
| `UAE-C15` | 2026-09-29 | 5 | ChatGPT | uae-q29 | **label** | "…It has been shown to reduce body weight by up to 16.6% in clinical trials.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C15` | 2026-09-29 | 5 | Claude | uae-f05 | **label** | "…vy pill is a 25 mg tablet licensed for weight loss and produced an average weight loss of 13.6% in trials…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C15` | 2026-09-29 | 5 | Claude | uae-f01 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct]; "…Clinical trials show Wegovy patients achieve approximately 15-18% weight loss over 68 weeks, while Ozempic results…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Clinical trials show Wegovy patients achieve approximately 15-18% weight loss over 68 weeks, while Ozempic results…" 18% → label [E-STEP3-tp, E-STEPUP-2.4-tp, E-TEENS-bmi-tp] |
| `UAE-C15` | 2026-09-29 | 5 | Claude | uae-f04 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6% compared to Foundayo's 12.4%…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C15` | 2026-09-29 | 5 | Claude | uae-f02 | **no-source** | "…round 20% weight loss over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…round 20% weight loss over six months at the top dose, and Wegovy (semaglutide) at around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…f 22.5% of their starting body weight, while those taking Wegovy 7.2mg lost an average of 21%…" 21% → label [E-STEPUP-7.2-tp] |
| `UAE-C15` | 2026-09-29 | 5 | Claude | uae-q27 | **no-source** | "…Wegovy (semaglutide) achieves around 12 to 15% weight loss over 12 months when paired with lifes…" 12% → no-source; "…Wegovy (semaglutide) achieves around 12 to 15% weight loss over 12 months when paired with lifes…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C15` | 2026-09-29 | 5 | Claude | uae-q31 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks.…" 13.6% → label [L-OASIS4-pct]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C15` | 2026-09-29 | 5 | Claude | uae-q29 | **label** | "…ht with Wegovy compared with Saxenda—in a 68-week study, people taking Wegovy lost nearly 16% of their starting weight, on average, compared wi…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C15` | 2026-09-29 | 5 | Claude | uae-q04 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C15` | 2026-09-29 | 5 | Claude | uae-f06 | **label** | "…that patients who took Saxenda lost 6.4% of their body weight over 68 weeks, compared to 15.8% with Wegovy.…" 15.8% → label [E-STEP8-pct] |
| `UAE-C15` | 2026-09-29 | 5 | Claude | uae-f03 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C15` | 2026-09-29 | 5 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C15` | 2026-09-29 | 5 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C15` | 2026-09-29 | 5 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C15` | 2026-09-29 | 5 | Gemini | uae-f01 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source |
| `UAE-C15` | 2026-09-29 | 5 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C15` | 2026-09-29 | 5 | Gemini | uae-q04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C15` | 2026-09-29 | 5 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C15` | 2026-09-29 | 5 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C15` | 2026-09-29 | 5 | Gemini | uae-q23 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C15` | 2026-09-29 | 5 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C15` | 2026-09-29 | 5 | Gemini | uae-q13 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-q21 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-q22 | **label** | "…Oral Wegovy is also now available, reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-q18 | **no-source** | "…Wegovy (semaglutide) delivers around 12 to 15% weight loss over 12 months when paired with lifes…" 12% → no-source; "…Wegovy (semaglutide) delivers around 12 to 15% weight loss over 12 months when paired with lifes…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-q17 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C16` | 2026-10-04 | 5 | ChatGPT | uae-f05 | **label** | "…eight loss with Wegovy, with participants achieving an average reduction of approximately 14.9% of their body weight over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C16` | 2026-10-04 | 5 | ChatGPT | uae-q04 | **label** | "…Clinical trials have demonstrated an average weight loss of approximately 15% over 68 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C16` | 2026-10-04 | 5 | ChatGPT | uae-f01 | **label** | "…linical trials have demonstrated that Wegovy leads to a mean weight loss of approximately 17%, whereas Ozempic has shown a mean weight loss of…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C16` | 2026-10-04 | 5 | ChatGPT | uae-q29 | **label** | "…Studies indicate an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C16` | 2026-10-04 | 5 | ChatGPT | uae-f02 | **label** | "…linical trials have shown that Wegovy can lead to an average weight loss of approximately 18.8% over 72 weeks at the highest dose.…" 18.8% → label [L-STEPUP-7.2-pct-fda] |
| `UAE-C16` | 2026-10-04 | 5 | ChatGPT | uae-f06 | **label** | "…: Clinical studies have shown that Wegovy can lead to a mean weight loss of approximately 17% in adults with obesity or overweight conditions.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-f05 | **label** | "…y pill is a 25 mg tablet licensed for weight loss, and produced an average weight loss of 13.6% in trials…" 13.6% → label [L-OASIS4-pct]; "…- Significantly better results (13.6% vs. 4-5% weight loss)…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-q14 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-f04 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-f01 | **label** | "…Clinical trials show Wegovy patients achieve approximately 15-18% weight loss over 68 weeks, while Ozempic results…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Clinical trials show Wegovy patients achieve approximately 15-18% weight loss over 68 weeks, while Ozempic results…" 18% → label [E-STEP3-tp, E-STEPUP-2.4-tp, E-TEENS-bmi-tp]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-q23 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-q27 | **label** | "…Semaglutide (branded as Ozempic for diabetes, Wegovy for weight loss) produces an average 14.9% body weight loss over 68 weeks in the STEP 1 tria…" 14.9% → label [L-STEP1-pct] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-f02 | **label** | "…sing an average of 20.2% (22.8 kg) of body weight compared with Wegovy users who averaged 13.7% (15 kg) loss.…" 13.7% → label [E-STEP9-pct]; "…average of 20.2% (22.8 kg) of body weight compared with Wegovy users who averaged 13.7% (15 kg) loss.…" 15kg → label [E-STEP1-kg, E-STEP8-kg, E-STEPUPT2D-7.2-kg, …] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-q31 | **label** | "…Trial data show average weight loss of about 16.6 per cent with…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-f06 | **label** | "…Wegovy produces 15.8% weight loss vs 6.4% with Saxenda in a head-to-hea…" 15.8% → label [E-STEP8-pct]; "…The highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-f03 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C16` | 2026-10-04 | 5 | Gemini | uae-f01 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C16` | 2026-10-04 | 5 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C16` | 2026-10-04 | 5 | Perplexity | uae-f04 | **label** | "…- Why it’s good: UAE reporting and trial data say oral Wegovy can produce about 16.6% to 17% average weight loss over roughly 64–68 weeks in p…" 16.6% → label [E-OASIS4-tp]; "…- Why it’s good: UAE reporting and trial data say oral Wegovy can produce about 16.6% to 17% average weight loss over roughly 64–68 weeks in p…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C16` | 2026-10-04 | 5 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C16` | 2026-10-04 | 5 | Perplexity | uae-f06 | **label** | "…: UAE clinic sources describe semaglutide-based options such as Wegovy as producing about 10–15% average body-weight loss in clinical trials, whil…" 10% → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; "…: UAE clinic sources describe semaglutide-based options such as Wegovy as producing about 10–15% average body-weight loss in clinical trials, whil…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C16` | 2026-10-04 | 5 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C16` | 2026-10-04 | 5 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C16` | 2026-10-04 | 5 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP8-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C16` | 2026-10-04 | 5 | Gemini | uae-q04 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C16` | 2026-10-04 | 5 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C16` | 2026-10-04 | 5 | Gemini | uae-q23 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-q20 | **label** | "…edical conditions achieved a 20% reduction in body weight, with an average weight loss of 15%.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C16` | 2026-10-04 | 5 | Claude | uae-q13 | **label** | "…Trial data show average weight loss of about 16.6 per cent with the oral form.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C16` | 2026-10-04 | 5 | Perplexity | uae-q25 | **label** | "…de (Mounjaro) as major options, with clinical-trial-level weight loss often cited around ~15% for semaglutide and ~22% for tirzepatide over lon…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C16` | 2026-10-04 | 5 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-q19 | **label** | "…People lost an average of 15% (up to 20%) body weight in a 68 week clinical tri…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-q21 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-q26 | **label** | "…People lost an average of 15% (up to 20%) body weight in a 68 week clinical tri…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-q17 | **label** | "…[sentence S3 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-q28 | **label** | "…[sentence S2 of withheld page P61]…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C18` | 2026-10-06 | 5 | ChatGPT | uae-f05 | **label** | "…ignificant weight loss, with participants achieving an average reduction of approximately 14.9% of their body weight over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C18` | 2026-10-06 | 5 | ChatGPT | uae-f02 | **label** | "…In the STEP trials, participants experienced an average weight loss of about 15% over 68–72 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C18` | 2026-10-06 | 5 | ChatGPT | uae-q29 | **label** | "…Clinical trials have shown an average weight loss of approximately 15% over 68 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C18` | 2026-10-06 | 5 | ChatGPT | uae-q23 | **label** | "…Clinical studies have demonstrated an average weight loss of approximately 15% over 68 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C18` | 2026-10-06 | 5 | ChatGPT | uae-q04 | **label** | "…- Efficacy: Clinical trials have demonstrated an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C18` | 2026-10-06 | 5 | ChatGPT | uae-q31 | **label** | "…It has demonstrated an average weight loss of 15% in clinical trials.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-f05 | **label** | "…The highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-f01 | **label** | "…Clinical trials show Wegovy patients achieve approximately 15-18% weight loss over 68 weeks, while Ozempic results…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Clinical trials show Wegovy patients achieve approximately 15-18% weight loss over 68 weeks, while Ozempic results…" 18% → label [E-STEP3-tp, E-STEPUP-2.4-tp, E-TEENS-bmi-tp]; "…Delivers superior weight loss results (15-18% vs. 8-14%)…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Delivers superior weight loss results (15-18% vs. 8-14%)…" 18% → label [E-STEP3-tp, E-STEPUP-2.4-tp, E-TEENS-bmi-tp]; "…Delivers superior weight loss results (15-18% vs. 8-14%)…" 8% → label [L-STEP4-pct]; "…Delivers superior weight loss results (15-18% vs. 8-14%)…" 14% → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-f04 | **label** | "…Wegovy pill provides a mean weight loss of 17% and is the only weight-loss pill approved to redu…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…Clinical trials showed the once-daily 25 mg Wegovy pill delivered an average 17% weight loss, with about 1 in 3 participants achie…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-q23 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp]; "…People lost an average of 15% (up to 20%) body weight in a 68 week clinical tri…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-q31 | **label** | "…Semaglutide produces an average 14.9% body weight loss over 68 weeks in the STEP 1 tria…" 14.9% → label [L-STEP1-pct] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-f02 | **label** | "…ent direct comparison found tirzepatide users lost about 15% of their weight, compared to 8% for semaglutide users after 1 year.…" 8% → label [L-STEP4-pct]; "…f 22.5% of their starting body weight, while those taking Wegovy 7.2mg lost an average of 21%.…" 21% → label [E-STEPUP-7.2-tp]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-q27 | **label** | "…Injectable semaglutide produces 10-16% body weight reduction in clinical trials.…" 10% → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; "…Injectable semaglutide produces 10-16% body weight reduction in clinical trials.…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; "…effective for weight loss than Wegovy, with an average weight loss of 20.02% compared to 13.7% with Wegovy.…" 13.7% → label [E-STEP9-pct]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-f06 | **label** | "…The Wegovy group lost an average of roughly 16% of their initial body weight.…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; "…Once-daily 25 mg oral semaglutide demonstrated ~17% mean weight loss in trials; about 1 in 3 particip…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-q29 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C18` | 2026-10-06 | 5 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C18` | 2026-10-06 | 5 | Gemini | uae-f01 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C18` | 2026-10-06 | 5 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C18` | 2026-10-06 | 5 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C18` | 2026-10-06 | 5 | Perplexity | uae-f04 | **label** | "…ngful weight loss: UAE reporting on the OASIS 4 data says the oral version produced about 16.6% average weight loss in adherent patients, with ab…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C18` | 2026-10-06 | 5 | Gemini | uae-f02 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C18` | 2026-10-06 | 5 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C18` | 2026-10-06 | 5 | Perplexity | uae-q04 | **label** | "…-1 medicines achieved about 12–14% mean weight reduction in trials, compared with roughly 15% for injectable semaglutide and 20% for tirzepatid…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C18` | 2026-10-06 | 5 | Gemini | uae-q23 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C18` | 2026-10-06 | 5 | Gemini | uae-q04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C18` | 2026-10-06 | 5 | Gemini | uae-q29 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-q20 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C18` | 2026-10-06 | 5 | Claude | uae-q06 | **no-source** | "…Results show tirzepatide led to −20.2% weight reduction compared to −13.7% with semaglutide at week 72.…" 13.7% → label [E-STEP9-pct]; "…weight than those who initiated semaglutide, with tirzepatide users losing 10.2 kg versus 6.1 kg for semaglutide users.…" 6.1kg → no-source |
| `UAE-C18` | 2026-10-06 | 5 | Gemini | uae-q06 | **congress** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → congress [C-OCTANE-pct] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q02 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q19 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q22 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q26 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q18 | **label** | "…Trial data show the oral formulation delivering around 17 per cent mean body weight reduction at 64 weeks…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q17 | **label** | "…[sentence S3 of withheld page P61]…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C19` | 2026-10-07 | 5 | Gemini | uae-q17 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C19` | 2026-10-07 | 5 | ChatGPT | uae-f01 | **label** | "…trials have demonstrated that Wegovy can lead to an average weight loss of approximately 15% of body weight.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C19` | 2026-10-07 | 5 | ChatGPT | uae-f04 | **label** | "…inical studies have shown that Wegovy can lead to an average weight loss of approximately 15% over a period of 14 months.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C19` | 2026-10-07 | 5 | ChatGPT | uae-f02 | **label** | "…In the STEP-1 trial, participants experienced an average weight loss of 13.7% over 68–72 weeks.…" 13.7% → label [E-STEP9-pct] |
| `UAE-C19` | 2026-10-07 | 5 | ChatGPT | uae-f03 | **label** | "…ignificant weight loss, with participants achieving an average reduction of approximately 17% of their body weight.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C19` | 2026-10-07 | 5 | ChatGPT | uae-q27 | **label** | "…injectable GLP-1 receptor agonist that has demonstrated an average weight loss of around 15% over 68 weeks in clinical studies.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…t has been shown to produce significant weight loss results, with an average reduction of 13.6% over 64 weeks in clinical trials.…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C19` | 2026-10-07 | 5 | ChatGPT | uae-f05 | **label** | "…trials have demonstrated significant weight loss, with participants losing an average of 14.9% of their body weight over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C19` | 2026-10-07 | 5 | ChatGPT | uae-q29 | **label** | "…Studies indicate an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q14 | **label** | "…[sentence S3 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-f01 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-f04 | **label** | "…The once-daily 25 mg Wegovy pill delivered an average 17% weight loss in clinical trials, with about 1 in 3…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6% compared to Foundayo's 12.4%…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C19` | 2026-10-07 | 5 | Gemini | uae-f01 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-f02 | **label** | "…f 22.5% of their starting body weight, while those taking Wegovy 7.2mg lost an average of 21%.…" 21% → label [E-STEPUP-7.2-tp]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to other oral options.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q23 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp]; "…Oral Wegovy reduces body weight by up to 16.6 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-f03 | **label** | "…Clinical data from the OASIS 4 trial showed participants achieving an average 17 percent weight reduction when adhering to the 25 mg daily…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q27 | **label** | "…t alternative to Zepbound is Wegovy (semaglutide), another injectable GLP-1 that produces 15% average body weight loss.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…The highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-f06 | **label** | "…The Wegovy group lost an average of roughly 16% of their initial body weight compared to about 6%…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; "…Once-daily 25 mg oral semaglutide demonstrated ~17% mean weight loss with adherence; about 1 in 3 par…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q29 | **label** | "…se more weight with Wegovy compared with Saxenda, with people taking Wegovy losing nearly 16% of their starting weight on average, compared wit…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C19` | 2026-10-07 | 5 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C19` | 2026-10-07 | 5 | Perplexity | uae-f05 | **label** | "…\| Expected weight loss \| Around 15% on average over roughly 68 weeks when combined wi…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C19` | 2026-10-07 | 5 | Perplexity | uae-f06 | **label** | "…\| Average weight loss \| About 15.8% over 68 weeks in a direct comparison \| About 6.4%…" 15.8% → label [E-STEP8-pct] |
| `UAE-C19` | 2026-10-07 | 5 | Perplexity | uae-f02 | **no-source** | "…ght loss \| Generally higher—around 20% or more in high-dose studies[1][3] \| Approximately 12–17% in commonly cited studies[1][3] \|…" 12% → no-source; "…ght loss \| Generally higher—around 20% or more in high-dose studies[1][3] \| Approximately 12–17% in commonly cited studies[1][3] \|…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C19` | 2026-10-07 | 5 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C19` | 2026-10-07 | 5 | Perplexity | uae-f03 | **label** | "…k comparison, tirzepatide produced approximately 20.2% average weight loss, compared with 13.7% for Wegovy.[2] Therefore, if both were equally ac…" 13.7% → label [E-STEP9-pct]; "…\| Average weight loss \| About 14% in the head-to-head trial[2] \| About 20% in the h…" 14% → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C19` | 2026-10-07 | 5 | Perplexity | uae-f04 | **label** | "…Eligible users may lose roughly 10–17% of body weight over about a year, provided they t…" 10% → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; "…Eligible users may lose roughly 10–17% of body weight over about a year, provided they t…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C19` | 2026-10-07 | 5 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp] |
| `UAE-C19` | 2026-10-07 | 5 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C19` | 2026-10-07 | 5 | Perplexity | uae-q31 | **label** | "…emaglutide \| Weekly injection specifically designed for chronic weight management \| About 15% over 68 weeks with lifestyle support[4][6] \| Clos…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C19` | 2026-10-07 | 5 | Perplexity | uae-q04 | **label** | "…govy (semaglutide 2.4 mg) \| Closest established alternative for weight management \| About 15% average weight loss in trials \| Weekly injection;…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…erage weight loss; cited comparisons place tirzepatide around 20–21% versus approximately 15% for Wegovy.[4]…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C19` | 2026-10-07 | 5 | Gemini | uae-q23 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q08 | **label** | "…[sentence S2 of withheld page P61], though these are prescription prod…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C19` | 2026-10-07 | 5 | Claude | uae-q20 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C19` | 2026-10-07 | 5 | Gemini | uae-q06 | **congress** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → congress [C-OCTANE-pct] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q21 | **label** | "…[sentence S2 of withheld page P61]…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q22 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q26 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q18 | **label** | "…Trial data show the oral formulation delivering around 17 per cent mean body weight reduction at 64 weeks, broadly c…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q19 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q17 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C20` | 2026-10-08 | 5 | Gemini | uae-q28 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C20` | 2026-10-08 | 5 | ChatGPT | uae-f05 | **label** | "…For instance, the STEP-1 trial reported an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C20` | 2026-10-08 | 5 | ChatGPT | uae-q29 | **label** | "…Studies indicate an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C20` | 2026-10-08 | 5 | ChatGPT | uae-q27 | **label** | "…injectable GLP-1 receptor agonist that has demonstrated an average weight loss of around 15% over 68 weeks in clinical trials.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C20` | 2026-10-08 | 5 | ChatGPT | uae-f02 | **label** | "…trials have demonstrated that Wegovy can lead to an average weight loss of approximately 15–17% of initial body weight over a 72-week period.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…trials have demonstrated that Wegovy can lead to an average weight loss of approximately 15–17% of initial body weight over a 72-week period.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C20` | 2026-10-08 | 5 | ChatGPT | uae-f01 | **label** | "…ant weight reduction, with some studies reporting an average weight loss of approximately 15% of body weight over a year.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C20` | 2026-10-08 | 5 | ChatGPT | uae-f04 | **label** | "…ignificant weight loss, with participants achieving an average reduction of approximately 15% of their body weight over a 14-month period.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C20` | 2026-10-08 | 5 | ChatGPT | uae-q31 | **label** | "…It has demonstrated an average weight loss of 14.9% in clinical trials.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C20` | 2026-10-08 | 5 | ChatGPT | uae-f06 | **label** | "…- Wegovy: Clinical studies have demonstrated a mean weight loss of approximately 17% in adults with obesity or overweight conditions w…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-f05 | **label** | "…The highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-f04 | **label** | "…The once-daily 25 mg Wegovy pill delivered an average 17% weight loss, with about 1 in 3 participants achie…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-f01 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp]; "…- You want stronger weight-loss results (up to 16.6%)…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C20` | 2026-10-08 | 5 | Gemini | uae-q14 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q31 | **label** | "…Clinical trials show that Wegovy can help patients lose an average of 15% of their body weight over 68 weeks when paired wi…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q04 | **no-source** | "…Trial data show average weight loss of about 16.6 per cent with the oral form, comparable to the 2.4mg injec…" 16.6% → label [E-OASIS4-tp]; "…to 21 pounds, while semaglutide effects are generally less pronounced, ranging from about 5 to 11 pounds…" 2.3kg(conv) → no-source; "…to 21 pounds, while semaglutide effects are generally less pronounced, ranging from about 5 to 11 pounds…" 5kg(conv) → no-source |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-f02 | **label** | "…f 22.5% of their starting body weight, while those taking Wegovy 7.2mg lost an average of 21%.…" 21% → label [E-STEPUP-7.2-tp]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q23 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q27 | **label** | "…t alternative to Zepbound is Wegovy (semaglutide), another injectable GLP-1 that produces 15% average body weight loss.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp]; "…Semaglutide (branded as Ozempic for diabetes, Wegovy for weight loss) produces an average 14.9% body weight loss over 68 weeks in the STEP 1 tria…" 14.9% → label [L-STEP1-pct] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q29 | **label** | "…In a 68-week study, people taking Wegovy lost nearly 16% of their starting weight, on average, compared wi…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-f03 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-f06 | **label** | "…Once-daily 25 mg oral semaglutide demonstrated ~17% mean weight loss in trials; about 1 in 3 particip…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…The Wegovy group lost an average of roughly 16% of their initial body weight.…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; "…tter for weight loss than Saxenda, as after 72 weeks, there was an average weight loss of 21% on Wegovy.…" 21% → label [E-STEPUP-7.2-tp] |
| `UAE-C20` | 2026-10-08 | 5 | Perplexity | uae-f01 | **label** | "…\| Expected weight loss \| Trial data generally show roughly 15–17% average loss over about 68 weeks in eligible adul…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…\| Expected weight loss \| Trial data generally show roughly 15–17% average loss over about 68 weeks in eligible adul…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C20` | 2026-10-08 | 5 | Perplexity | uae-f05 | **label** | "…\| Expected weight loss \| Around 15% over 68 weeks in the pivotal STEP 1 trial when co…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C20` | 2026-10-08 | 5 | Perplexity | uae-f03 | **label** | "…\| Typical weight loss in direct comparison \| About 13.7% after 72 weeks \| About 20.2% after 72 weeks[1] \|…" 13.7% → label [E-STEP9-pct] |
| `UAE-C20` | 2026-10-08 | 5 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C20` | 2026-10-08 | 5 | Gemini | uae-f01 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C20` | 2026-10-08 | 5 | Perplexity | uae-f02 | **label** | "…eight loss \| Generally around 20% or more at higher doses in clinical data[1][4] \| Around 15% in the pivotal STEP 1 trial[2][4] \|…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…r average weight loss: approximately 20% or more at effective higher doses versus roughly 15% with Wegovy[1][2][4].…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C20` | 2026-10-08 | 5 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C20` | 2026-10-08 | 5 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C20` | 2026-10-08 | 5 | Perplexity | uae-f04 | **label** | "…- Effectiveness: The injection typically produces around 15% average weight loss over roughly 15 months with d…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C20` | 2026-10-08 | 5 | Gemini | uae-q31 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C20` | 2026-10-08 | 5 | Perplexity | uae-f06 | **label** | "…\| Average weight loss \| About 15.8% over 68 weeks in a direct comparison \| About 6.4%…" 15.8% → label [E-STEP8-pct] |
| `UAE-C20` | 2026-10-08 | 5 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP8-pct] |
| `UAE-C20` | 2026-10-08 | 5 | Perplexity | uae-q04 | **label** | "…vy (semaglutide 2.4 mg) \| Best direct alternative for chronic weight management \| Roughly 15–17% average weight loss in trials and clinical summar…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…vy (semaglutide 2.4 mg) \| Best direct alternative for chronic weight management \| Roughly 15–17% average weight loss in trials and clinical summar…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C20` | 2026-10-08 | 5 | Perplexity | uae-q31 | **label** | "…tide 2.4 mg) \| The closest like-for-like weight-management alternative to Ozempic \| About 15% in the STEP 1 trial[2][7] \| Specifically designed…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q20 | **label** | "…[sentence S2 of withheld page P61]…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q13 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C20` | 2026-10-08 | 5 | Claude | uae-q06 | **no-source** | "…squares mean percent change in weight at week 72 was −20.2% with tirzepatide compared to −13.7% with semaglutide.…" 13.7% → label [E-STEP9-pct]; "…ide experienced greater average weight loss than those receiving semaglutide (−11.15% vs −8.83%), with more patients achieving clinically meaning…" 8.83% → no-source |
| `UAE-C20` | 2026-10-08 | 5 | Gemini | uae-q20 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C20` | 2026-10-08 | 5 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-q26 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-q19 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-q22 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-q17 | **label** | "…[sentence S3 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C21` | 2026-10-09 | 5 | Gemini | uae-q17 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C21` | 2026-10-09 | 5 | ChatGPT | uae-f04 | **label** | "…ignificant weight loss, with participants achieving an average reduction of approximately 15% of their body weight.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C21` | 2026-10-09 | 5 | ChatGPT | uae-q04 | **label** | "…In the STEP 1 trial, participants lost an average of 14.9% of their body weight over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C21` | 2026-10-09 | 5 | ChatGPT | uae-q27 | **label** | "…-weekly injectable GLP-1 receptor agonist that has demonstrated an average weight loss of 14.9% over 68 weeks in clinical studies.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C21` | 2026-10-09 | 5 | ChatGPT | uae-f05 | **label** | "…ignificant weight loss, with participants achieving an average reduction of approximately 14.9% of their body weight over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C21` | 2026-10-09 | 5 | ChatGPT | uae-q29 | **label** | "…Clinical trials have demonstrated an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-f05 | **label** | "…The highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct]; "…weight loss than Rybelsus, with adults taking the 25 mg Wegovy pill losing an average of 13.6% of their body weight over 64 weeks, compared with…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-q14 | **label** | "…[sentence S3 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-f01 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-q29 | **label** | "…In a 68-week study, people taking Wegovy lost nearly 16% of their starting weight, on average, compared wi…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-q27 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp]; "…t alternative to Zepbound is Wegovy (semaglutide), another injectable GLP-1 that produces 15% average body weight loss.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…effective for weight loss than Wegovy, with an average weight loss of 20.02% compared to 13.7% with Wegovy.…" 13.7% → label [E-STEP9-pct] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-f02 | **label** | "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-q23 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-f06 | **label** | "…The Wegovy group lost an average of roughly 16% of their initial body weight.…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C21` | 2026-10-09 | 5 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-kg, E-STEP8-kg, E-STEPUPT2D-7.2-kg, …] |
| `UAE-C21` | 2026-10-09 | 5 | Gemini | uae-f03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C21` | 2026-10-09 | 5 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct] |
| `UAE-C21` | 2026-10-09 | 5 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C21` | 2026-10-09 | 5 | Perplexity | uae-f04 | **no-source** | "…UAE reports indicate average losses around 12–17% of body weight with appropriate treatment, alongs…" 12% → no-source; "…UAE reports indicate average losses around 12–17% of body weight with appropriate treatment, alongs…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C21` | 2026-10-09 | 5 | Perplexity | uae-f05 | **label** | "…\| Weight-loss potential \| Higher-dose semaglutide; trials report about 15% average loss over 68 weeks with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C21` | 2026-10-09 | 5 | Perplexity | uae-f06 | **label** | "…\| Average weight loss in head-to-head evidence \| About 15.8–16% after roughly 68 weeks[6][9] \| About 6.4% after r…" 15.8% → label [E-STEP8-pct]; "…\| Average weight loss in head-to-head evidence \| About 15.8–16% after roughly 68 weeks[6][9] \| About 6.4% after r…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C21` | 2026-10-09 | 5 | Perplexity | uae-f02 | **label** | "…\| Average weight loss \| About 15% over 68 weeks in the STEP 1 trial[1] \| About 20%…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…The head-to-head trial found approximately 20% average weight loss with Mounjaro versus 14% with Wegovy after 72 weeks.[6] This is an average…" 14% → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C21` | 2026-10-09 | 5 | Perplexity | uae-f03 | **label** | "…\| Expected weight loss \| About 13.7% at 72 weeks in the standard-dose head-to-head com…" 13.7% → label [E-STEP9-pct]; "…maximum average weight loss: Zepbound/tirzepatide, with trial averages around 20% versus 14% for standard-dose Wegovy.[1][3]…" 14% → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C21` | 2026-10-09 | 5 | Gemini | uae-q27 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-q04 | **label** | "…trial data show average weight loss of about 16.6 per cent with the oral form…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-f03 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C21` | 2026-10-09 | 5 | Gemini | uae-q29 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C21` | 2026-10-09 | 5 | Perplexity | uae-q04 | **label** | "…govy (semaglutide 2.4 mg) \| Closest established alternative for obesity treatment \| About 15% average weight reduction in cited comparisons[1]…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…es \| Generally less than tirzepatide; semaglutide weight-loss results are commonly around 15–17% at obesity-treatment doses[1] \| Widely available…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…es \| Generally less than tirzepatide; semaglutide weight-loss results are commonly around 15–17% at obesity-treatment doses[1] \| Widely available…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C21` | 2026-10-09 | 5 | Gemini | uae-q31 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C21` | 2026-10-09 | 5 | Gemini | uae-q23 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-q24 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C21` | 2026-10-09 | 5 | Claude | uae-q20 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C21` | 2026-10-09 | 5 | Gemini | uae-q16 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct] |
| `UAE-C21` | 2026-10-09 | 5 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP4-pct] |
| `UAE-C21` | 2026-10-09 | 5 | Perplexity | uae-q25 | **label** | "…\| Wegovy (semaglutide 2.4 mg) \| Roughly 10–15% on average, with some patients exceeding 15–20% \| Weekly injection; usually one of the most comme…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…A patient starting at 100 kg might therefore lose roughly 10–15 kg with an effective semaglutide programme, 15–20 kg…" 10kg → label [E-STEP2-kg]; "…A patient starting at 100 kg might therefore lose roughly 10–15 kg with an effective semaglutide programme, 15–20 kg…" 15kg → label [E-STEP1-kg, E-STEP8-kg, E-STEPUPT2D-7.2-kg, …] |
| `UAE-C21` | 2026-10-09 | 5 | Perplexity | uae-q06 | **no-source** | "…\| Semaglutide 2.4 mg — Wegovy \| Large randomized trials generally show roughly 12–15% average weight loss over about 68 weeks, alongsid…" 12% → no-source; "…\| Semaglutide 2.4 mg — Wegovy \| Large randomized trials generally show roughly 12–15% average weight loss over about 68 weeks, alongsid…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-q19 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C22` | 2026-10-10 | 5 | ChatGPT | uae-f05 | **label** | "…ignificant weight loss, with participants achieving an average reduction of approximately 14.9% of their body weight over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C22` | 2026-10-10 | 5 | ChatGPT | uae-f04 | **label** | "…ignificant weight loss, with participants achieving an average reduction of approximately 17% of their body weight.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C22` | 2026-10-10 | 5 | ChatGPT | uae-f02 | **label** | "…linical trials have shown that Wegovy can lead to an average weight loss of approximately 15% over 68–72 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C22` | 2026-10-10 | 5 | ChatGPT | uae-q31 | **label** | "…Clinical studies indicate an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-f04 | **label** | "…The once-daily 25 mg Wegovy pill delivered an average 17% weight loss, with about 1 in 3 participants achie…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-f05 | **label** | "…The highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-q14 | **label** | "…[sentence S3 of withheld page P61]…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-q27 | **label** | "…t alternative to Zepbound is Wegovy (semaglutide), another injectable GLP-1 that produces 15% average body weight loss.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…effective for weight loss than Wegovy, with an average weight loss of 20.02% compared to 13.7% with Wegovy.…" 13.7% → label [E-STEP9-pct]; "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp]; "…Semaglutide (branded as Ozempic for diabetes, Wegovy for weight loss) produces an average 14.9% body weight loss over 68 weeks in the STEP 1 tria…" 14.9% → label [L-STEP1-pct] |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-q29 | **label** | "…In a 68-week study, people taking Wegovy lost nearly 16% of their starting weight, on average, compared wi…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-q04 | **no-source** | "…to 21 pounds, while semaglutide effects are generally less pronounced, ranging from about 5 to 11 pounds…" 2.3kg(conv) → no-source; "…to 21 pounds, while semaglutide effects are generally less pronounced, ranging from about 5 to 11 pounds…" 5kg(conv) → no-source |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-q23 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp]; "…Oral Wegovy reduces body weight by up to 16.6 per cent.…" 16.6% → label [E-OASIS4-tp]; "…edical conditions achieved a 20% reduction in body weight, with an average weight loss of 15%.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-f02 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-f03 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-f06 | **label** | "…The Wegovy group lost an average of roughly 16% of their initial body weight.…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C22` | 2026-10-10 | 5 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C22` | 2026-10-10 | 5 | Gemini | uae-f01 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C22` | 2026-10-10 | 5 | Perplexity | uae-f05 | **label** | "…\| Average weight-loss evidence \| About 15% over 68 weeks with lifestyle support[1][2] \| Roug…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…In the STEP 1 trial, participants lost approximately 15% of body weight on average over 68 weeks when Wego…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C22` | 2026-10-10 | 5 | Perplexity | uae-f02 | **label** | "…15% with the standard 2.4 mg injection; the oral 25 mg version reportedly produced about 16.6% in trials[2][10] \|…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C22` | 2026-10-10 | 5 | Gemini | uae-f02 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C22` | 2026-10-10 | 5 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C22` | 2026-10-10 | 5 | Perplexity | uae-f03 | **label** | "…\| Average weight loss \| About 14% in the standard-dose head-to-head comparison[4] \|…" 14% → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; "…Zepbound produced approximately 20% average weight loss versus 14% with Wegovy in a direct comparison, although indi…" 14% → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C22` | 2026-10-10 | 5 | Perplexity | uae-f06 | **label** | "…\| Typical trial weight loss \| About 15% over roughly 68 weeks \| About 8% over roughly 56…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C22` | 2026-10-10 | 5 | Gemini | uae-f03 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C22` | 2026-10-10 | 5 | Perplexity | uae-q31 | **label** | "…r weight management; availability can be less consistent than Mounjaro or Ozempic \| About 15% on average[1][4] \| Supply and price may vary; wee…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C22` | 2026-10-10 | 5 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-OASIS4-tp] |
| `UAE-C22` | 2026-10-10 | 5 | Perplexity | uae-q04 | **label** | "…Wegovy (semaglutide 2.4 mg) \| Closest approved alternative for obesity treatment \| About 15% average weight loss in trials \| Weekly injection;…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C22` | 2026-10-10 | 5 | Gemini | uae-q29 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C22` | 2026-10-10 | 5 | Gemini | uae-q23 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp] |
| `UAE-C22` | 2026-10-10 | 5 | Gemini | uae-q04 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-q13 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C22` | 2026-10-10 | 5 | Claude | uae-q20 | **label** | "…[sentence S2 of withheld page P61]…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C22` | 2026-10-10 | 5 | Gemini | uae-q03 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C22` | 2026-10-10 | 5 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C22` | 2026-10-10 | 5 | Perplexity | uae-q25 | **label** | "…weighing 100 kg might lose approximately 5–10 kg through a well-run lifestyle programme, 10–15 kg with semaglutide-based treatment, and potentially…" 10kg → label [E-STEP2-kg]; "…weighing 100 kg might lose approximately 5–10 kg through a well-run lifestyle programme, 10–15 kg with semaglutide-based treatment, and potentially…" 15kg → label [E-STEP1-kg, E-STEP8-kg, E-STEPUPT2D-7.2-kg, …] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-q19 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-q18 | **label** | "…the oral formulation delivering around 17 per cent mean body weight reduction at 64 weeks…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-q26 | **label** | "…[sentence S2 of withheld page P61]…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C23` | 2026-10-11 | 5 | ChatGPT | uae-f04 | **label** | "…ed its effectiveness, with participants achieving an average weight loss of approximately 15% of their body weight.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C23` | 2026-10-11 | 5 | ChatGPT | uae-f02 | **label** | "…In the STEP trials, participants experienced an average weight loss of about 15% over 68–72 weeks.…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C23` | 2026-10-11 | 5 | ChatGPT | uae-f05 | **label** | "…Wegovy, administered as a weekly injection, leads to a mean weight loss of approximately 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C23` | 2026-10-11 | 5 | ChatGPT | uae-f03 | **label** | "…maglutide can lead to significant weight loss, with an average reduction of approximately 17% of body weight.…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C23` | 2026-10-11 | 5 | ChatGPT | uae-q31 | **label** | "…Clinical trials have demonstrated an average weight loss of 14.9% over 68 weeks.…" 14.9% → label [L-STEP1-pct] |
| `UAE-C23` | 2026-10-11 | 5 | ChatGPT | uae-f06 | **label** | "…- Wegovy: Clinical studies have demonstrated a mean weight loss of approximately 17% in adults with obesity or overweight conditions w…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-f05 | **label** | "…Adults with overweight or obesity who took the 25 mg Wegovy pill lost an average of 13.6% of their body weight over 64 weeks…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-q14 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-f04 | **label** | "…the once-daily 25 mg Wegovy pill delivered an average 17% weight loss, with about 1 in 3 participants achie…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-f01 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-f02 | **no-source** | "…% weight loss over six months at the top dose, while Wegovy (semaglutide) achieves around 12 to 15% over 12 months when paired with lifestyle support…" 12% → no-source; "…% weight loss over six months at the top dose, while Wegovy (semaglutide) achieves around 12 to 15% over 12 months when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…In trials, the highest 25mg Wegovy pill achieved about 13.6% weight loss in 64 weeks, compared with 11.1% over…" 13.6% → label [L-OASIS4-pct] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-q27 | **no-source** | "…Wegovy delivers around 12 to 15% average weight loss over 12 months when paired wi…" 12% → no-source; "…Wegovy delivers around 12 to 15% average weight loss over 12 months when paired wi…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…Wegovy is another injectable GLP-1 that produces 15% average body weight loss…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-q04 | **label** | "…Average weight loss with Wegovy is around 15% over 68 weeks when paired with lifestyle support…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…(Mounjaro) achieved 47% greater relative weight loss than semaglutide, with 20.2% versus 13.7% body weight reduction…" 13.7% → label [E-STEP9-pct] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-q29 | **label** | "…ht with Wegovy compared with Saxenda—in a 68-week study, people taking Wegovy lost nearly 16% of their starting weight, on average, compared wi…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-q23 | **label** | "…Oral Wegovy reduces body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent…" 16.6% → label [E-OASIS4-tp]; "…Oral Wegovy reduces body weight by up to 16.6 per cent…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-f06 | **label** | "…eight compared to those using Saxenda, with the Wegovy group losing an average of roughly 16% of their initial body weight compared to about 6%…" 16% → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …]; "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-f03 | **label** | "…ble GLP-1 therapies remain more effective, with oral Wegovy reducing body weight by up to 16.6 per cent compared to Foundayo's 12.4 per cent.…" 16.6% → label [E-OASIS4-tp]; "…- Need maximum weight loss results (20%+ vs. 16.6% for Wegovy)…" 16.6% → label [E-OASIS4-tp] |
| `UAE-C23` | 2026-10-11 | 5 | Gemini | uae-f04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP5-kg]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-kg]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C23` | 2026-10-11 | 5 | Perplexity | uae-f01 | **label** | "…cted weight loss \| Stronger evidence at the obesity dose; clinical studies report roughly 15–17% average loss in suitable patients.[6][8] \| Can pr…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…cted weight loss \| Stronger evidence at the obesity dose; clinical studies report roughly 15–17% average loss in suitable patients.[6][8] \| Can pr…" 17% → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C23` | 2026-10-11 | 5 | Perplexity | uae-f05 | **label** | "…\| Expected weight loss \| Around 15% average weight loss over 68 weeks in the major ST…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C23` | 2026-10-11 | 5 | Gemini | uae-f05 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct] |
| `UAE-C23` | 2026-10-11 | 5 | Perplexity | uae-f03 | **label** | "…\| Average weight loss \| About 13.7% in a head-to-head trial \| About 20.2% in the same…" 13.7% → label [E-STEP9-pct]; "…he direct comparison, tirzepatide produced approximately 20.2% average weight loss versus 13.7% with Wegovy after 72 weeks.[1][2] This does not g…" 13.7% → label [E-STEP9-pct] |
| `UAE-C23` | 2026-10-11 | 5 | Gemini | uae-f01 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP2-pct, L-STEP6-1.7-pct, L-STEPUPT2D-2.4-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct] |
| `UAE-C23` | 2026-10-11 | 5 | Gemini | uae-f02 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEPUP-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C23` | 2026-10-11 | 5 | Gemini | uae-f03 | **no-source** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP9-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → no-source; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C23` | 2026-10-11 | 5 | Perplexity | uae-f06 | **label** | "…\| Typical trial weight loss \| About 15% over 68 weeks \| About 8% over 56 weeks[1][2] \|…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; "…tide 2.4 mg over liraglutide for average weight reduction; separate trials report roughly 15% for Wegovy versus about 8% for Saxenda.[1][2]…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C23` | 2026-10-11 | 5 | Gemini | uae-f06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEPUP-7.2-pct-fda, E-STEPUP-7.2-pct]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-OASIS4-pct, E-STEP9-pct, E-STEPUPT2D-7.2-tp]; [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP8-pct] |
| `UAE-C23` | 2026-10-11 | 5 | Perplexity | uae-q31 | **label** | "…\| Wegovy (semaglutide 2.4 mg) \| A purpose-designed weight-management alternative \| About 15% on average \| Same active ingredient family as Oze…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C23` | 2026-10-11 | 5 | Perplexity | uae-q04 | **label** | "…\| Wegovy (semaglutide 2.4 mg) \| Closest approved weight-management alternative \| About 15% average weight reduction in trials[1] \| Weekly in…" 15% → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |
| `UAE-C23` | 2026-10-11 | 5 | Gemini | uae-q29 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP3-pct, L-STEPUP-2.4-pct-fda, L-TEENS-bmi-pct, …] |
| `UAE-C23` | 2026-10-11 | 5 | Gemini | uae-q04 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [E-STEP1-tp, E-STEP5-tp, E-STEP8-tp, …] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-q24 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C23` | 2026-10-11 | 5 | Claude | uae-q20 | **label** | "…[sentence S2 of withheld page P61].…" [figure beside a withheld sentence of page P61] → label [reference values withheld] |
| `UAE-C23` | 2026-10-11 | 5 | Gemini | uae-q06 | **label** | [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …]; [Gemini answer text withheld] [Gemini figure text withheld] → label [L-STEP1-pct, L-TEENS-wt-pct, E-STEP5-pct, …] |

## 6. E5: first-line framing (Singapore)

Candidates (text search, lib.ts E5_CANDIDATE): **264**. Codes: e5-first-line-general 0 · e5-first-line-high-risk 2 · e5-first-line-with-metformin 63 · e5-not-first-line 199 · UNCODED 0.

| Series | Cycle | Date | v | Window | Perplexity | Gemini | ChatGPT | Claude |
|---|---|---|---|---|---|---|---|---|
| singapore-sglt2 | `SG-C01` | 2026-08-22 | 4 | before-v4 | not-first-line 2 [22] | first-line-with-metformin 1, not-first-line 8 [26] | first-line-with-metformin 1, not-first-line 1 [26] | first-line-with-metformin 2, not-first-line 2 [26] |
| singapore-sglt2 | `SG-C02` | 2026-08-24 | 4 | before-v4 | not-first-line 2 [26] | first-line-with-metformin 2, not-first-line 7 [26] | first-line-with-metformin 1 [26] | first-line-with-metformin 3, not-first-line 5 [26] |
| singapore-sglt2 | `SG-C03` | 2026-08-26 | 4 | before-v4 | 0 [26] | first-line-with-metformin 1, not-first-line 10 [26] | 0 [26] | first-line-with-metformin 1, not-first-line 1 [26] |
| singapore-sglt2 | `SG-C04` | 2026-08-28 | 4 | before-v4 | 0 [26] | first-line-with-metformin 3, not-first-line 6 [26] | not-first-line 1 [26] | not-first-line 1 [26] |
| singapore-sglt2 | `SG-C05` | 2026-08-30 | 4 | before-v4 | 0 [26] | first-line-with-metformin 3, not-first-line 5 [26] | 0 [26] | first-line-with-metformin 1, not-first-line 2 [26] |
| singapore-sglt2 | `SG-C06` | 2026-09-04 | 4 | before-v4 | 0 [26] | first-line-with-metformin 5, not-first-line 9 [26] | 0 [26] | not-first-line 1 [26] |
| singapore-sglt2 | `SG-C07` | 2026-09-06 | 4 | before-v4 | 0 [26] | first-line-with-metformin 2, not-first-line 8 [26] | 0 [26] | first-line-with-metformin 2, not-first-line 1 [26] |
| singapore-sglt2 | `SG-C08` | 2026-09-08 | 4 | before-v4 | not-first-line 1 [26] | first-line-with-metformin 2, not-first-line 4 [26] | 0 [26] | first-line-with-metformin 1, not-first-line 1 [26] |
| singapore-sglt2 | `SG-C09` | 2026-09-10 | 4 | before-v4 | 0 [26] | first-line-with-metformin 3, not-first-line 7 [26] | not-first-line 1 [26] | first-line-with-metformin 1, not-first-line 1 [26] |
| singapore-sglt2 | `SG-C10` | 2026-09-13 | 4 | before-v4 | 0 [26] | not-first-line 9 [26] | not-first-line 1 [26] | not-first-line 1 [26] |
| singapore-sglt2 | `SG-C11` | 2026-09-15 | 4 | before-v4 | not-first-line 1 [26] | first-line-with-metformin 2, not-first-line 8 [26] | 0 [26] | first-line-with-metformin 1, not-first-line 3 [26] |
| singapore-sglt2 | `SG-C12` | 2026-09-17 | 4 | before-v4 | 0 [26] | first-line-with-metformin 2, not-first-line 11 [26] | not-first-line 1 [26] | not-first-line 2 [26] |
| singapore-sglt2 | `SG-C13` | 2026-09-19 | 4 | before-v4 | 0 [26] | first-line-with-metformin 2, not-first-line 7 [25] | 0 [26] | first-line-with-metformin 1, not-first-line 2 [26] |
| singapore-sglt2 | `SG-C14` | 2026-09-21 | 4 | before-v4 | 0 [25] | first-line-high-risk 1, first-line-with-metformin 2, not-first-line 8 [26] | 0 [26] | first-line-with-metformin 1 [26] |
| singapore-sglt2 | `SG-C15` | 2026-09-26 | 4 | before-v4 | not-first-line 1 [26] | first-line-with-metformin 2, not-first-line 9 [26] | 0 [26] | not-first-line 2 [26] |
| singapore-sglt2 | `SG-C17` | 2026-10-02 | 5 | during | 0 [26] | first-line-with-metformin 3, not-first-line 5 [26] | 0 [26] | first-line-with-metformin 1 [26] |
| singapore-sglt2 | `SG-C18` | 2026-10-05 | 5 | after | 0 [26] | first-line-with-metformin 3, not-first-line 4 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C19` | 2026-10-06 | 5 | after | first-line-with-metformin 1 [26] | not-first-line 8 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C20` | 2026-10-07 | 5 | after | first-line-with-metformin 1, not-first-line 1 [26] | first-line-with-metformin 1, not-first-line 5 [26] | 0 [26] | first-line-with-metformin 1 [26] |
| singapore-sglt2 | `SG-C21` | 2026-10-08 | 5 | after | 0 [26] | first-line-with-metformin 1, not-first-line 8 [26] | 0 [26] | first-line-with-metformin 1 [26] |
| singapore-sglt2 | `SG-C22` | 2026-10-09 | 5 | after | 0 [26] | first-line-high-risk 1, first-line-with-metformin 1, not-first-line 8 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C23` | 2026-10-10 | 5 | after | first-line-with-metformin 1 [26] | not-first-line 2 [26] | 0 [26] | 0 [26] |
| singapore-sglt2 | `SG-C24` | 2026-10-11 | 5 | after | 0 [26] | not-first-line 5 [26] | 0 [26] | 0 [26] |

### Ledger

| Cycle | Date | v | Engine | prompt_id | Terms | Code | Qualifying span | Note |
|---|---|---|---|---|---|---|---|---|
| `SG-C01` | 2026-08-22 | 4 | Claude | sg-q18 | first-line | **e5-first-line-with-metformin** | "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c" | — |
| `SG-C01` | 2026-08-22 | 4 | Gemini | sg-q11 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C01` | 2026-08-22 | 4 | Gemini | sg-q17 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C01` | 2026-08-22 | 4 | ChatGPT | sg-q10 | initial | **e5-first-line-with-metformin** | "It is indicated for the treatment of type 2 diabetes mellitus and is also used in combination with metformin for initial therapy." | — |
| `SG-C01` | 2026-08-22 | 4 | Perplexity | sg-q01 | monotherapy | **e5-not-first-line** | "They have low hypoglycaemia risk on monotherapy" | — |
| `SG-C01` | 2026-08-22 | 4 | Gemini | sg-q01 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C01` | 2026-08-22 | 4 | ChatGPT | sg-q09 | monotherapy | **e5-not-first-line** | "as monotherapy or as an add-on combination therapy with other glucose-lowering agents, including insulin" | — |
| `SG-C01` | 2026-08-22 | 4 | Claude | sg-q19 | first-line | **e5-first-line-with-metformin** | "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c." | — |
| `SG-C01` | 2026-08-22 | 4 | Claude | sg-q06 | monotherapy | **e5-not-first-line** | "low hypoglycaemia risk on monotherapy" | — |
| `SG-C01` | 2026-08-22 | 4 | Claude | sg-q12 | monotherapy | **e5-not-first-line** | "low hypoglycaemia risk on monotherapy" | — |
| `SG-C01` | 2026-08-22 | 4 | Gemini | sg-f02 | initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C01` | 2026-08-22 | 4 | Gemini | sg-q12 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C01` | 2026-08-22 | 4 | Gemini | sg-q02 | initial, monotherapy | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C01` | 2026-08-22 | 4 | Gemini | sg-q06 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C01` | 2026-08-22 | 4 | Gemini | sg-f05 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C01` | 2026-08-22 | 4 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C01` | 2026-08-22 | 4 | Perplexity | sg-q16 | first-line | **e5-not-first-line** | "metformin is still a standard first-line option, but it is not an SGLT2 inhibitor" | — |
| `SG-C02` | 2026-08-24 | 4 | ChatGPT | sg-q10 | monotherapy, initial | **e5-first-line-with-metformin** | "Forxiga® is approved as an initial combination therapy with metformin" | — |
| `SG-C02` | 2026-08-24 | 4 | Gemini | sg-q18 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C02` | 2026-08-24 | 4 | Claude | sg-q17 | first-line | **e5-first-line-with-metformin** | "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c" | — |
| `SG-C02` | 2026-08-24 | 4 | Gemini | sg-q03 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C02` | 2026-08-24 | 4 | Claude | sg-q10 | monotherapy | **e5-not-first-line** | "low hypoglycaemia risk on monotherapy" | — |
| `SG-C02` | 2026-08-24 | 4 | Perplexity | sg-q05 | monotherapy | **e5-not-first-line** | "though it is not a pure SGLT2 inhibitor monotherapy" | — |
| `SG-C02` | 2026-08-24 | 4 | Claude | sg-q05 | monotherapy | **e5-not-first-line** | "low hypoglycaemia risk on monotherapy" | — |
| `SG-C02` | 2026-08-24 | 4 | Gemini | sg-q01 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C02` | 2026-08-24 | 4 | Gemini | sg-q11 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C02` | 2026-08-24 | 4 | Claude | sg-q19 | first-line | **e5-first-line-with-metformin** | "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c." | — |
| `SG-C02` | 2026-08-24 | 4 | Claude | sg-f01 | first-line | **e5-first-line-with-metformin** | "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c" | — |
| `SG-C02` | 2026-08-24 | 4 | Gemini | sg-q09 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C02` | 2026-08-24 | 4 | Claude | sg-q08 | monotherapy | **e5-not-first-line** | "SGLT2 inhibitors are the preferred addition when metformin monotherapy is insufficient" | — |
| `SG-C02` | 2026-08-24 | 4 | Claude | sg-q12 | monotherapy | **e5-not-first-line** | "can be given as monotherapy or in combination with other medications" | — |
| `SG-C02` | 2026-08-24 | 4 | Claude | sg-f02 | first-line, initial | **e5-not-first-line** | "Jardiance is often chosen as a first-line treatment due to its additional cardiovascular benefits demonstrated in clinical trials, while Invokana might be considered if a patient doesn't respond well to initial therapy" | First-line framing with no reference to metformin; the comparison is within the SGLT2 class (ambiguity A7). |
| `SG-C02` | 2026-08-24 | 4 | Gemini | sg-q07 | initial | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C02` | 2026-08-24 | 4 | Gemini | sg-q06 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C02` | 2026-08-24 | 4 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C02` | 2026-08-24 | 4 | Perplexity | sg-q02 | first-line | **e5-not-first-line** | "not the brand most Singapore consumers would typically use as a first-line local purchase" | Non-clinical use of 'first-line'. |
| `SG-C02` | 2026-08-24 | 4 | Gemini | sg-q08 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C03` | 2026-08-26 | 4 | Gemini | sg-q03 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C03` | 2026-08-26 | 4 | Gemini | sg-q14 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C03` | 2026-08-26 | 4 | Gemini | sg-q11 | monotherapy, initial, first-line | **e5-not-first-line** | [Gemini answer text withheld] | Canagliflozin described as second-line: the inverse framing. |
| `SG-C03` | 2026-08-26 | 4 | Gemini | sg-q01 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C03` | 2026-08-26 | 4 | Gemini | sg-q09 | first-line, monotherapy | **e5-first-line-with-metformin** | [Gemini answer text withheld] | 'Especially' widens the population beyond high-risk patients, but metformin stays the base. |
| `SG-C03` | 2026-08-26 | 4 | Gemini | sg-q19 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C03` | 2026-08-26 | 4 | Claude | sg-q02 | monotherapy | **e5-not-first-line** | "low hypoglycaemia risk on monotherapy" | — |
| `SG-C03` | 2026-08-26 | 4 | Claude | sg-q07 | monotherapy, initial | **e5-first-line-with-metformin** | "Forxiga® (dapagliflozin): Also indicated as an initial combination therapy with metformin." | — |
| `SG-C03` | 2026-08-26 | 4 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C03` | 2026-08-26 | 4 | Gemini | sg-q07 | initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C03` | 2026-08-26 | 4 | Gemini | sg-q06 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C03` | 2026-08-26 | 4 | Gemini | sg-q16 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C03` | 2026-08-26 | 4 | Gemini | sg-q08 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C04` | 2026-08-28 | 4 | ChatGPT | sg-q15 | initially | **e5-not-first-line** | "Initially included in the SDL, dapagliflozin 5 mg and 10 mg tablets will be delisted" | Non-clinical use of 'initially'. |
| `SG-C04` | 2026-08-28 | 4 | Gemini | sg-q10 | monotherapy, first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C04` | 2026-08-28 | 4 | Gemini | sg-q15 | monotherapy, first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C04` | 2026-08-28 | 4 | Gemini | sg-q18 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C04` | 2026-08-28 | 4 | Gemini | sg-q14 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C04` | 2026-08-28 | 4 | Gemini | sg-q19 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C04` | 2026-08-28 | 4 | Gemini | sg-q09 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C04` | 2026-08-28 | 4 | Claude | sg-q12 | monotherapy | **e5-not-first-line** | "with low hypoglycaemia risk on monotherapy" | — |
| `SG-C04` | 2026-08-28 | 4 | Gemini | sg-q16 | initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C04` | 2026-08-28 | 4 | Gemini | sg-q08 | initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C04` | 2026-08-28 | 4 | Gemini | sg-q02 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C05` | 2026-08-30 | 4 | Claude | sg-q15 | initial | **e5-first-line-with-metformin** | "Forxiga® is indicated as an initial combination therapy with metformin" | — |
| `SG-C05` | 2026-08-30 | 4 | Gemini | sg-q18 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C05` | 2026-08-30 | 4 | Claude | sg-q17 | monotherapy | **e5-not-first-line** | "low hypoglycaemia risk on monotherapy" | — |
| `SG-C05` | 2026-08-30 | 4 | Gemini | sg-q14 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C05` | 2026-08-30 | 4 | Gemini | sg-q01 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C05` | 2026-08-30 | 4 | Gemini | sg-q17 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C05` | 2026-08-30 | 4 | Claude | sg-f03 | monotherapy | **e5-not-first-line** | "indicated for type 2 diabetes mellitus in adults and children aged 10 years and above as monotherapy or in combination with other glucose-lowering medicinal products" | — |
| `SG-C05` | 2026-08-30 | 4 | Gemini | sg-q16 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C05` | 2026-08-30 | 4 | Gemini | sg-q07 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C05` | 2026-08-30 | 4 | Gemini | sg-q06 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C05` | 2026-08-30 | 4 | Gemini | sg-q08 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Claude | sg-q05 | monotherapy | **e5-not-first-line** | "is available as a monotherapy option, though it is less commonly prescribed than the first three." | 'Monotherapy option' states an indication, not a first-line position (ambiguity A8). |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-q05 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-q15 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-q11 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-q03 | monotherapy, first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-q17 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-q14 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-q09 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-f06 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-f01 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-q16 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-q06 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-q02 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C06` | 2026-09-04 | 4 | Gemini | sg-q08 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C07` | 2026-09-06 | 4 | Gemini | sg-q15 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C07` | 2026-09-06 | 4 | Claude | sg-q05 | first-line | **e5-first-line-with-metformin** | "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c" | — |
| `SG-C07` | 2026-09-06 | 4 | Claude | sg-q01 | first-line | **e5-not-first-line** | "Not recommended as first-line choice locally" | Negative framing for one named SGLT2 inhibitor (a 'con'); the inverse of first-line. |
| `SG-C07` | 2026-09-06 | 4 | Gemini | sg-q18 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C07` | 2026-09-06 | 4 | Gemini | sg-q11 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C07` | 2026-09-06 | 4 | Gemini | sg-q01 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C07` | 2026-09-06 | 4 | Gemini | sg-q14 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C07` | 2026-09-06 | 4 | Gemini | sg-q09 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C07` | 2026-09-06 | 4 | Claude | sg-q07 | monotherapy, first-line | **e5-first-line-with-metformin** | "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c." | — |
| `SG-C07` | 2026-09-06 | 4 | Gemini | sg-q04 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C07` | 2026-09-06 | 4 | Gemini | sg-q12 | initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C07` | 2026-09-06 | 4 | Gemini | sg-q06 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C07` | 2026-09-06 | 4 | Gemini | sg-q08 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C08` | 2026-09-08 | 4 | Claude | sg-q10 | first-line | **e5-first-line-with-metformin** | "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c" | — |
| `SG-C08` | 2026-09-08 | 4 | Claude | sg-q01 | monotherapy | **e5-not-first-line** | "low hypoglycaemia risk on monotherapy" | — |
| `SG-C08` | 2026-09-08 | 4 | Gemini | sg-q03 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C08` | 2026-09-08 | 4 | Perplexity | sg-q01 | monotherapy | **e5-not-first-line** | "low hypoglycaemia risk on monotherapy" | — |
| `SG-C08` | 2026-09-08 | 4 | Gemini | sg-q01 | monotherapy, initial | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C08` | 2026-09-08 | 4 | Gemini | sg-q18 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C08` | 2026-09-08 | 4 | Gemini | sg-q06 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C08` | 2026-09-08 | 4 | Gemini | sg-q08 | monotherapy, initial, first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C08` | 2026-09-08 | 4 | Gemini | sg-q02 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Inverse framing (second-line). |
| `SG-C09` | 2026-09-10 | 4 | Gemini | sg-q13 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Inverse framing (second-line) for the class. |
| `SG-C09` | 2026-09-10 | 4 | Gemini | sg-q17 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C09` | 2026-09-10 | 4 | Gemini | sg-q18 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C09` | 2026-09-10 | 4 | Gemini | sg-q03 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C09` | 2026-09-10 | 4 | Gemini | sg-q01 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C09` | 2026-09-10 | 4 | Gemini | sg-q11 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C09` | 2026-09-10 | 4 | Gemini | sg-q10 | initial | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C09` | 2026-09-10 | 4 | ChatGPT | sg-f04 | monotherapy | **e5-not-first-line** | "both as monotherapy and in combination with other antidiabetic agents" | — |
| `SG-C09` | 2026-09-10 | 4 | Claude | sg-f07 | initial | **e5-not-first-line** | "it may be another viable option for patients requiring second-line therapy after metformin" | Inverse framing (second-line after metformin). |
| `SG-C09` | 2026-09-10 | 4 | Gemini | sg-f03 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C09` | 2026-09-10 | 4 | Claude | sg-f06 | initial | **e5-first-line-with-metformin** | "Forxiga (dapagliflozin) is indicated as initial combination therapy with metformin" | — |
| `SG-C09` | 2026-09-10 | 4 | Gemini | sg-q08 | first-line, monotherapy | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C09` | 2026-09-10 | 4 | Gemini | sg-q07 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C10` | 2026-09-13 | 4 | ChatGPT | sg-q15 | initially | **e5-not-first-line** | "Initially included in the SDL, dapagliflozin 5 mg and 10 mg tablets will be delisted" | Non-clinical use of 'initially'. |
| `SG-C10` | 2026-09-13 | 4 | Gemini | sg-q15 | initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C10` | 2026-09-13 | 4 | Claude | sg-q18 | monotherapy | **e5-not-first-line** | "low hypoglycaemia risk on monotherapy" | — |
| `SG-C10` | 2026-09-13 | 4 | Gemini | sg-q18 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Inverse framing (canagliflozin second-line). |
| `SG-C10` | 2026-09-13 | 4 | Gemini | sg-q13 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C10` | 2026-09-13 | 4 | Gemini | sg-q03 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C10` | 2026-09-13 | 4 | Gemini | sg-q01 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C10` | 2026-09-13 | 4 | Gemini | sg-q02 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C10` | 2026-09-13 | 4 | Gemini | sg-q08 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C10` | 2026-09-13 | 4 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C10` | 2026-09-13 | 4 | Gemini | sg-q06 | initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C11` | 2026-09-15 | 4 | Claude | sg-q03 | monotherapy | **e5-not-first-line** | "low hypoglycaemia risk on monotherapy" | — |
| `SG-C11` | 2026-09-15 | 4 | Gemini | sg-q05 | initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C11` | 2026-09-15 | 4 | Gemini | sg-q15 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C11` | 2026-09-15 | 4 | Gemini | sg-q03 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C11` | 2026-09-15 | 4 | Gemini | sg-q10 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C11` | 2026-09-15 | 4 | Gemini | sg-q01 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C11` | 2026-09-15 | 4 | Claude | sg-q17 | initial, monotherapy | **e5-first-line-with-metformin** | "Indicated as an initial combination therapy with metformin" | Under the dapagliflozin entry. |
| `SG-C11` | 2026-09-15 | 4 | Perplexity | sg-q01 | monotherapy | **e5-not-first-line** | "low hypoglycaemia risk on monotherapy" | — |
| `SG-C11` | 2026-09-15 | 4 | Gemini | sg-q19 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C11` | 2026-09-15 | 4 | Claude | sg-q02 | first-line | **e5-not-first-line** | "making it the government's recommended first-line SGLT2 inhibitor in Singapore" | 'First-line' WITHIN the SGLT2 class (preferred SGLT2 inhibitor), not relative to metformin (ambiguity A7). |
| `SG-C11` | 2026-09-15 | 4 | Gemini | sg-f03 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | The same paragraph calls the class second-line and first-line add-on. |
| `SG-C11` | 2026-09-15 | 4 | Claude | sg-q04 | monotherapy | **e5-not-first-line** | "Available as monotherapy and in fixed-dose combinations (Jardiance Duo® with metformin)." | — |
| `SG-C11` | 2026-09-15 | 4 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C11` | 2026-09-15 | 4 | Gemini | sg-q06 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C11` | 2026-09-15 | 4 | Gemini | sg-q08 | initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C12` | 2026-09-17 | 4 | ChatGPT | sg-q10 | monotherapy | **e5-not-first-line** | "either as monotherapy or in combination with other glucose-lowering agents" | — |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-q11 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-q10 | initial, monotherapy | **e5-first-line-with-metformin** | [Gemini answer text withheld] | Under the dapagliflozin entry. |
| `SG-C12` | 2026-09-17 | 4 | Claude | sg-q17 | first-line | **e5-not-first-line** | "Empagliflozin is the MOH-recommended first-line option, with dapagliflozin being delisted from the subsidized drugs list" | 'First-line' within the SGLT2 class on subsidy grounds, not relative to metformin (ambiguity A7). |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-q17 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-q18 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-q03 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-q01 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C12` | 2026-09-17 | 4 | Claude | sg-q09 | monotherapy | **e5-not-first-line** | "empagliflozin monotherapy or add-on therapy improved glycaemic control" | Trial description, not a position statement. |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-q09 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-q07 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | 'Preferred choice … regardless of HbA1c' compares SGLT2 agents for high-risk patients; it states no position relative to metformin (ambiguity A9). |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-q16 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-f04 | initial | **e5-not-first-line** | [Gemini answer text withheld] | Non-clinical use of 'initial'. |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-f07 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C12` | 2026-09-17 | 4 | Gemini | sg-f05 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C13` | 2026-09-19 | 4 | Gemini | sg-q15 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C13` | 2026-09-19 | 4 | Gemini | sg-q18 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C13` | 2026-09-19 | 4 | Claude | sg-q13 | monotherapy | **e5-not-first-line** | "The standard starting dose is 10 mg once daily for monotherapy and combination therapy with other medications" | — |
| `SG-C13` | 2026-09-19 | 4 | Gemini | sg-q10 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C13` | 2026-09-19 | 4 | Claude | sg-q17 | first-line | **e5-first-line-with-metformin** | "are now first-line add-ons to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease" | — |
| `SG-C13` | 2026-09-19 | 4 | Gemini | sg-q03 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C13` | 2026-09-19 | 4 | Gemini | sg-q17 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C13` | 2026-09-19 | 4 | Gemini | sg-q01 | initial, monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C13` | 2026-09-19 | 4 | Claude | sg-q08 | initially | **e5-not-first-line** | "some patients who are new users may have low blood pressure and feel faint initially" | — |
| `SG-C13` | 2026-09-19 | 4 | Gemini | sg-q12 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C13` | 2026-09-19 | 4 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C13` | 2026-09-19 | 4 | Gemini | sg-q07 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C14` | 2026-09-21 | 4 | Gemini | sg-q03 | initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C14` | 2026-09-21 | 4 | Gemini | sg-q11 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Inverse framing (second-line). |
| `SG-C14` | 2026-09-21 | 4 | Gemini | sg-q10 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | 'Add-on' with metformin implied, not named (ambiguity A6). |
| `SG-C14` | 2026-09-21 | 4 | Gemini | sg-q13 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C14` | 2026-09-21 | 4 | Claude | sg-q17 | first-line | **e5-first-line-with-metformin** | "SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c." | — |
| `SG-C14` | 2026-09-21 | 4 | Gemini | sg-q05 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C14` | 2026-09-21 | 4 | Gemini | sg-q01 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | 'Preferred choice … regardless of HbA1c' states no position relative to metformin (ambiguity A9). |
| `SG-C14` | 2026-09-21 | 4 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C14` | 2026-09-21 | 4 | Gemini | sg-f02 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C14` | 2026-09-21 | 4 | Gemini | sg-q06 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | No position relative to metformin (ambiguity A9). |
| `SG-C14` | 2026-09-21 | 4 | Gemini | sg-f05 | first-line | **e5-first-line-high-risk** | [Gemini answer text withheld] | First-line for high-risk patients with no mention of metformin; coded high-risk because nothing places it after or on top of metformin (ambiguity A6). |
| `SG-C14` | 2026-09-21 | 4 | Gemini | sg-q08 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C15` | 2026-09-26 | 4 | Gemini | sg-q10 | monotherapy, initial | **e5-first-line-with-metformin** | [Gemini answer text withheld] | Under the dapagliflozin entry. |
| `SG-C15` | 2026-09-26 | 4 | Claude | sg-q13 | monotherapy | **e5-not-first-line** | "Recommended starting dose is 10 mg once daily for monotherapy" | — |
| `SG-C15` | 2026-09-26 | 4 | Gemini | sg-q17 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C15` | 2026-09-26 | 4 | Claude | sg-q05 | first-line | **e5-not-first-line** | "metformin is the standard first-line drug, and if control is not good, SGLT2 inhibitors would be a very reasonable choice as a combination therapy" | Metformin first-line; SGLT2 inhibition second. |
| `SG-C15` | 2026-09-26 | 4 | Gemini | sg-q18 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C15` | 2026-09-26 | 4 | Perplexity | sg-q05 | monotherapy | **e5-not-first-line** | "rather than pure SGLT2 monotherapy" | — |
| `SG-C15` | 2026-09-26 | 4 | Gemini | sg-q03 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C15` | 2026-09-26 | 4 | Gemini | sg-q14 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C15` | 2026-09-26 | 4 | Gemini | sg-q01 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C15` | 2026-09-26 | 4 | Gemini | sg-f03 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C15` | 2026-09-26 | 4 | Gemini | sg-q07 | initial, first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | — |
| `SG-C15` | 2026-09-26 | 4 | Gemini | sg-f04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C15` | 2026-09-26 | 4 | Gemini | sg-q12 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C15` | 2026-09-26 | 4 | Gemini | sg-f05 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | — |
| `SG-C17` | 2026-10-02 | 5 | Gemini | sg-q18 | monotherapy, initial, first-line | **e5-not-first-line** | [Gemini answer text withheld] | States metformin is first-line and SGLT2 inhibitors second-line or add-on. |
| `SG-C17` | 2026-10-02 | 5 | Gemini | sg-q11 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C17` | 2026-10-02 | 5 | Gemini | sg-q10 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | First-line add-on to metformin, high-risk patients. |
| `SG-C17` | 2026-10-02 | 5 | Gemini | sg-q14 | initial | **e5-not-first-line** | [Gemini answer text withheld] | [Gemini answer text withheld] of side effects only. |
| `SG-C17` | 2026-10-02 | 5 | Gemini | sg-q17 | initial | **e5-not-first-line** | [Gemini answer text withheld] | [Gemini answer text withheld] only. |
| `SG-C17` | 2026-10-02 | 5 | Gemini | sg-q01 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C17` | 2026-10-02 | 5 | Claude | sg-q12 | first-line | **e5-first-line-with-metformin** | "n in adults with type 2 diabetes - SGLT2 inhibitors are now first-line add-on to metformin in any patient with established cardiovascular disease, heart failure or chronic kidney disease, regardless of HbA1c - Widely availabl" | First-line add-on to metformin regardless of HbA1c (high-risk patients). |
| `SG-C17` | 2026-10-02 | 5 | Gemini | sg-f06 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | First-line add-on to metformin, high-risk patients, regardless of HbA1c. |
| `SG-C17` | 2026-10-02 | 5 | Gemini | sg-f05 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | First-line add-ons (to metformin) for high-risk patients. |
| `SG-C18` | 2026-10-05 | 5 | Gemini | sg-q03 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | First-line add-on to metformin, high-risk patients. |
| `SG-C18` | 2026-10-05 | 5 | Gemini | sg-q11 | initial | **e5-not-first-line** | [Gemini answer text withheld] | [Gemini answer text withheld] of side effects only. |
| `SG-C18` | 2026-10-05 | 5 | Gemini | sg-q01 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C18` | 2026-10-05 | 5 | Gemini | sg-q07 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | First-line add-on to metformin, high-risk patients. |
| `SG-C18` | 2026-10-05 | 5 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Indicated as monotherapy or combination; no first-line framing. |
| `SG-C18` | 2026-10-05 | 5 | Gemini | sg-q02 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Use as monotherapy or combination described; no first-line position or comparison with metformin. |
| `SG-C18` | 2026-10-05 | 5 | Gemini | sg-f06 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | First-line add-on to metformin, high-risk patients. |
| `SG-C19` | 2026-10-06 | 5 | Gemini | sg-q17 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C19` | 2026-10-06 | 5 | Gemini | sg-q14 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C19` | 2026-10-06 | 5 | Perplexity | sg-q11 | initial | **e5-first-line-with-metformin** | "s are used for **type 2 diabetes**, and Forxiga also has an **initial combination with metformin** indication.[1][2] - SGLT2 inhibitors can cause **genital/urinary infections**, **low blood" | Initial combination with metformin (Forxiga indication). |
| `SG-C19` | 2026-10-06 | 5 | Gemini | sg-q11 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C19` | 2026-10-06 | 5 | Gemini | sg-q18 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C19` | 2026-10-06 | 5 | Gemini | sg-q01 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C19` | 2026-10-06 | 5 | Gemini | sg-q04 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C19` | 2026-10-06 | 5 | Gemini | sg-q02 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C19` | 2026-10-06 | 5 | Gemini | sg-f05 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Indicated as monotherapy or combination; no first-line framing. |
| `SG-C20` | 2026-10-07 | 5 | Gemini | sg-q15 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C20` | 2026-10-07 | 5 | Perplexity | sg-q11 | initial | **e5-first-line-with-metformin** | "rand; once daily; heart and kidney benefits; can be used in initial combination with metformin under its Singapore indication.[2][3] \| Dapagliflozin tablets were removed from" | Initial combination with metformin (Forxiga indication). |
| `SG-C20` | 2026-10-07 | 5 | Perplexity | sg-q10 | first-line | **e5-not-first-line** | "**Forxiga — equally serious first-line alternative** - Strong choice when chronic kidney disease or heart failure is part of the t" | Ambiguity A7 (as in the baseline: "first-line" within the SGLT2 class, not relative to metformin): "first-line alternative" ranks Forxiga against the other SGLT2 brands (second to Jardiance); the answer never places SGLT2 inhibition against metformin or in the type 2 diabetes treatment sequence. Read in full. |
| `SG-C20` | 2026-10-07 | 5 | Gemini | sg-q14 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C20` | 2026-10-07 | 5 | Gemini | sg-q03 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C20` | 2026-10-07 | 5 | Claude | sg-q12 | initial, monotherapy | **e5-first-line-with-metformin** | "e 2 diabetes mellitus, and Forxiga® is also indicated as an initial combination therapy with metformin - **Clinical benefits**: A large observational study found that the benefits of" | Initial combination with metformin (Forxiga indication); monotherapy named as flexibility only. |
| `SG-C20` | 2026-10-07 | 5 | Gemini | sg-q09 | first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | First-line add-on to metformin, high-risk patients, irrespective of HbA1c. |
| `SG-C20` | 2026-10-07 | 5 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Indicated as monotherapy or add-on; no first-line framing. |
| `SG-C20` | 2026-10-07 | 5 | Gemini | sg-q08 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C21` | 2026-10-08 | 5 | Gemini | sg-q18 | monotherapy, first-line | **e5-first-line-with-metformin** | [Gemini answer text withheld] | [Gemini answer text withheld]high-risk patients. |
| `SG-C21` | 2026-10-08 | 5 | Gemini | sg-q11 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C21` | 2026-10-08 | 5 | Gemini | sg-q13 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C21` | 2026-10-08 | 5 | Gemini | sg-q01 | initial, monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C21` | 2026-10-08 | 5 | Claude | sg-q12 | initial | **e5-first-line-with-metformin** | "making it more affordable - Forxiga is also indicated as an initial combination therapy with metformin - Forxiga is the brand name for dapagliflozin (made by AstraZeneca) ### 2. **Ja" | Initial combination with metformin (Forxiga indication). |
| `SG-C21` | 2026-10-08 | 5 | Gemini | sg-q02 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Indicated as monotherapy or combination; no first-line framing. |
| `SG-C21` | 2026-10-08 | 5 | Gemini | sg-q16 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Indicated as monotherapy or combination; no first-line framing. |
| `SG-C21` | 2026-10-08 | 5 | Gemini | sg-q07 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C21` | 2026-10-08 | 5 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C21` | 2026-10-08 | 5 | Gemini | sg-q08 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C22` | 2026-10-09 | 5 | Gemini | sg-q03 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C22` | 2026-10-09 | 5 | Gemini | sg-q10 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C22` | 2026-10-09 | 5 | Gemini | sg-q18 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C22` | 2026-10-09 | 5 | Gemini | sg-q01 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C22` | 2026-10-09 | 5 | Gemini | sg-q09 | first-line | **e5-first-line-high-risk** | [Gemini answer text withheld] | First-line for patients with cardiovascular or renal risk, with no mention of metformin; coded high-risk because nothing places it after or on top of metformin (ambiguity A6, as in the baseline). |
| `SG-C22` | 2026-10-09 | 5 | Gemini | sg-q19 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C22` | 2026-10-09 | 5 | Gemini | sg-q02 | initial | **e5-first-line-with-metformin** | [Gemini answer text withheld] | Initial combination with metformin (Forxiga indication). |
| `SG-C22` | 2026-10-09 | 5 | Gemini | sg-q07 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Indicated as monotherapy or combination; no first-line framing. |
| `SG-C22` | 2026-10-09 | 5 | Gemini | sg-q04 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Indicated as monotherapy or combination; no first-line framing. |
| `SG-C22` | 2026-10-09 | 5 | Gemini | sg-f05 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | States the label indication: monotherapy only when metformin is unsuitable, which keeps metformin first (ambiguity A8, as in the baseline). |
| `SG-C23` | 2026-10-10 | 5 | Gemini | sg-q18 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Indicated as monotherapy or combination; no first-line framing. |
| `SG-C23` | 2026-10-10 | 5 | Perplexity | sg-f01 | initial | **e5-first-line-with-metformin** | "\| Effective option for type 2 diabetes; also registered for initial combination treatment with metformin in Singapore.[1] \| \| Heart failure \| Strong evidence and approved use \| Strong" | Initial combination with metformin (Forxiga indication). |
| `SG-C23` | 2026-10-10 | 5 | Gemini | sg-q08 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |
| `SG-C24` | 2026-10-11 | 5 | Gemini | sg-q03 | initial | **e5-not-first-line** | [Gemini answer text withheld] | [Gemini answer text withheld] is side-effect timing, not a treatment position; no first-line framing in type 2 diabetes. |
| `SG-C24` | 2026-10-11 | 5 | Gemini | sg-q17 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Indicated as monotherapy or combination; no first-line framing. |
| `SG-C24` | 2026-10-11 | 5 | Gemini | sg-q01 | monotherapy, initial | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. [Gemini answer text withheld] elsewhere is side-effect timing. |
| `SG-C24` | 2026-10-11 | 5 | Gemini | sg-q02 | initial | **e5-not-first-line** | [Gemini answer text withheld] | [Gemini answer text withheld] for patients with cardiovascular, heart-failure or kidney disease, with no first-line or initial position and no position relative to metformin (as A9 in the baseline); [Gemini answer text withheld] matched side-effect timing. |
| `SG-C24` | 2026-10-11 | 5 | Gemini | sg-q08 | monotherapy | **e5-not-first-line** | [Gemini answer text withheld] | Monotherapy named only for low hypoglycaemia risk; no first-line framing in type 2 diabetes. |